1
|
Martinón-Torres F, Salamanca de la Cueva I, Horn M, Westerholt S, Bosis S, Meyer N, Cheuvart B, Virk N, Jakes RW, Duchenne M, Van den Steen P. Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule. Hum Vaccin Immunother 2024; 20:2342630. [PMID: 38687024 PMCID: PMC11062389 DOI: 10.1080/21645515.2024.2342630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2024] [Accepted: 04/10/2024] [Indexed: 05/02/2024] Open
Abstract
Since the introduction of Haemophilus Influenzae type b (Hib) conjugate vaccines, invasive Hib disease has strongly declined worldwide, yet continued control of Hib disease remains important. In Europe, currently three different hexavalent combination vaccines containing Hib conjugates are marketed. In this phase IV, single-blind, randomized, controlled, multi-country study (NCT04535037), we aimed to compare, in a 2 + 1 vaccination schedule, the immunogenicity and safety and show non-inferiority, as well as superiority, of DTPa-HBV-IPV/Hib (Ih group) versus DTaP5-HB-IPV-Hib (Va group) in terms of anti-polyribosylribitol phosphate (PRP) antibody geometric mean concentrations (GMCs) and proportion of participants reaching anti-PRP antibody concentrations greater than or equal to a threshold of 5 µg/mL. One month after the booster vaccination, the anti-PRP antibody GMC ratio (Ih group/Va group) was 0.917 (95% CI: 0.710-1.185), meeting the non-inferiority criteria. The difference in percentage of participants (Ih group - Va group) reaching GMCs ≥5 µg/mL was -6.3% (95% CI: -14.1% to 1.5%), not reaching the predefined non-inferiority threshold. Interestingly, a slightly higher post-booster antibody avidity was observed in the Ih group versus the Va group. Both vaccines were well tolerated, and no safety concerns were raised. This study illustrates the different kinetics of the anti-PRP antibody response post-primary and post-booster using the two vaccines containing different Hib conjugates and indicates a potential differential impact of concomitant vaccinations on the anti-PRP responses. The clinical implications of these differences should be further studied.
Collapse
MESH Headings
- Humans
- Haemophilus Vaccines/immunology
- Haemophilus Vaccines/adverse effects
- Haemophilus Vaccines/administration & dosage
- Antibodies, Bacterial/blood
- Infant
- Immunization Schedule
- Female
- Male
- Single-Blind Method
- Vaccines, Conjugate/immunology
- Vaccines, Conjugate/administration & dosage
- Vaccines, Conjugate/adverse effects
- Haemophilus influenzae type b/immunology
- Vaccines, Combined/immunology
- Vaccines, Combined/administration & dosage
- Vaccines, Combined/adverse effects
- Haemophilus Infections/prevention & control
- Haemophilus Infections/immunology
- Hepatitis B Vaccines/immunology
- Hepatitis B Vaccines/administration & dosage
- Hepatitis B Vaccines/adverse effects
- Poliovirus Vaccine, Inactivated/immunology
- Poliovirus Vaccine, Inactivated/administration & dosage
- Poliovirus Vaccine, Inactivated/adverse effects
- Diphtheria-Tetanus-Pertussis Vaccine/immunology
- Diphtheria-Tetanus-Pertussis Vaccine/administration & dosage
- Diphtheria-Tetanus-Pertussis Vaccine/adverse effects
- Child, Preschool
- Immunogenicity, Vaccine
- Europe
- Polysaccharides
Collapse
Affiliation(s)
- Federico Martinón-Torres
- Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain
- Genetics, Vaccines and Infectious Diseases Research Group (GENvip), Instituto de Investigación Sanitaria de Santiago, Universidad de Santiago de Compostela, Santiago de Compostela, Spain
- Consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain
| | | | - Michael Horn
- Praxis Dr. med. Michael Horn, Bayern, Schoenau am Koenigssee, Germany
| | - Soeren Westerholt
- Praxis für Kinder und Jugendmedizin Drs. Westerholt/Matyas, Wolfsburg, Germany
| | - Samantha Bosis
- Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy
| | | | | | | | | | | | | |
Collapse
|
2
|
Collin-Bund V, Viviani V, Meyer N, Goetsch T, Boisramé T, Faller E, Lecointre L, Gabriele V, Akladios C, Garbin O, Host A. Study of the feasibility of outpatient sacrocolpopexy by laparoscopy. J Gynecol Obstet Hum Reprod 2024; 53:102792. [PMID: 38663686 DOI: 10.1016/j.jogoh.2024.102792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2024] [Revised: 03/18/2024] [Accepted: 04/22/2024] [Indexed: 05/05/2024]
Abstract
INTRODUCTION Laparoscopic sacrocolpopexy (LSCP) is currently the gold standard surgical technique for treating pelvic prolapse. This study aimed to evaluate the feasibility of laparoscopic sacrocolpopexy in ambulatory care. PATIENTS AND METHODS This prospective study was conducted to evaluate the feasibility of LSCP in women who visited the outpatient department of obstetrics and gynecology at the University Hospital of Strasbourg between July 2018 and December 2021. All women with indications for laparoscopic sacrocolpopexy for prolapse treatment who were willing to be treated as outpatients were included. The main criterion of the study was to evaluate the rate of re-hospitalization between discharge from the outpatient department after LSCP and postoperative follow-up consultations. RESULTS Among the whole population (57/200, 28.5 %) included, 4 (7 %) were hospitalized. The quality of life was not altered with a preserved EuroQol (EQ-5D) quality of life score with a mean score of 73±18.4 standard deviation (SD) 95 % confidence interval (CI) (67.9; 78.1) on postoperative day 3 (D3) and 91.2 ± 16.3 SD 95 % CI (86.2-96) on D30. On D1, D2, D3, and D7, the anxiety rate evaluated by State-Trait Anxiety Inventory score (STAI Y-A) remained low, with mean scores of 24.8 ± 9.6 SD 95 % [23.4-26.5] on D30. All patients were satisfied or very satisfied with the procedure and outpatient management, with an average score of 9.6/10 (range: 8-10). CONCLUSION This prospective, monocentric study evaluating the feasibility of outpatient LSCP reported demonstrated low rates of complications and re-hospitalization after outpatient management. Furthermore, the patients' quality of life was not altered, and they patients were satisfied with this type of management.
Collapse
Affiliation(s)
- V Collin-Bund
- Department of Gynecologic Surgery, Strasbourg University Hospital, Strasbourg, France; Laboratoire d'ImmunoRhumatologie Moléculaire, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR_S 1109, Institut thématique interdisciplinaire (ITI) de Médecine de Précision de Strasbourg, Transplantex NG, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
| | - V Viviani
- Department of Gynecologic Surgery, Strasbourg University Hospital, Strasbourg, France
| | - N Meyer
- Department of Public Health, Biostatistic laboratory, Université de Strasbourg, 67081 Strasbourg, France
| | - T Goetsch
- Department of Public Health, Biostatistic laboratory, Université de Strasbourg, 67081 Strasbourg, France
| | - T Boisramé
- Department of Gynecologic Surgery, Strasbourg University Hospital, Strasbourg, France
| | - E Faller
- Department of Gynecologic Surgery, Strasbourg University Hospital, Strasbourg, France
| | - L Lecointre
- Department of Gynecologic Surgery, Strasbourg University Hospital, Strasbourg, France; I-Cube UMR 7357-Laboratoire des Sciences de L'ingénieur, de L'informatique et de L'imagerie, Université de Strasbourg, 67081 Strasbourg, France; Institut Hospitalo-Universitaire (IHU), Institute for Minimally Invasive Hybrid Image-Guided Surgery, Université de Strasbourg, 67081 Strasbourg, France
| | - V Gabriele
- Department of Gynecologic Surgery, Strasbourg University Hospital, Strasbourg, France
| | - C Akladios
- Department of Gynecologic Surgery, Strasbourg University Hospital, Strasbourg, France
| | - O Garbin
- Department of Gynecologic Surgery, Strasbourg University Hospital, Strasbourg, France
| | - A Host
- Department of Gynecologic Surgery, Strasbourg University Hospital, Strasbourg, France
| |
Collapse
|
3
|
Amini-Adle M, Arnault JP, Aubin F, Beneton N, Bens G, Brunet-Possenti F, Célerier P, Charles J, Crumbach L, Dalac S, Darras S, De Quatrebarbes J, Dinulescu M, Dutriaux C, Gaudy C, Gérard E, Giacchero D, Granel-Brocard F, Grange F, Jouary T, Kramkimel N, Lebbé C, Le Corre Y, Legoupil D, Lesage C, Lesimple T, Lorphelin JM, Mansard S, Martin L, Mary-Prey S, Maubec E, Meyer N, Mignard C, Montaudie H, Mortier L, Nardin C, Neidhardt Berard EM, Pagès Laurent C, Peuvrel L, Quereux G, Robert C, Saiag P, Saint-Jean M, Samimi M, Sassolas B, Scalbert C, Skowron F, Steff M, Stoebner PE, Trablesi S, Visseaux L, Zehou O, Boespflug A. The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns. Ann Dermatol Venereol 2024; 151:103243. [PMID: 38325268 DOI: 10.1016/j.annder.2023.103243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 04/06/2023] [Accepted: 09/05/2023] [Indexed: 02/09/2024]
Affiliation(s)
- M Amini-Adle
- Dermatology Department, Centre Léon Bérard, Lyon, France.
| | - J-P Arnault
- Dermatology Department, Centre Hospitalo-Universitaire, Amiens Picardie, France
| | - F Aubin
- Université de Bourgogne-Franche-Comté, Dermatology Department, Head of the Skin Cancer Unit, Centre Hospitalo-Universitaire de Besançon, Besançon, France; INSERM UMR RIGHT 1098, Besançon, France
| | - N Beneton
- Dermatology Department, Centre Hospitalier, Le Mans, France
| | - G Bens
- Dermatology Department, Centre Hospitalier, Orléans, France
| | - F Brunet-Possenti
- Dermatology Department, Centre Hospitalo-Universitaire Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - P Célerier
- Dermatology Department, Centre Hospitalier La Rochelle-Ré-Aunis, La Rochelle, France
| | - J Charles
- Dermatology Department, Centre Hospitalo-Universitaire, Grenoble, France
| | - L Crumbach
- Dermatology Department, Centre Léon Bérard, Lyon, France
| | - S Dalac
- Dermatology Department, Centre Hospitalo-Universitaire, Dijon, France
| | - S Darras
- Dermatology Department, Centre Hospitalier de Boulogne-sur-Mer, France
| | - J De Quatrebarbes
- Dermatology Department, Centre Hospitalier Annecy Genevois, Annecy, France
| | - M Dinulescu
- Dermatology Department, Centre Hospitalo-Universitaire, Rennes, France
| | - C Dutriaux
- Dermatology Department, Centre Hospitalo-Universitaire, Bordeaux, France
| | - C Gaudy
- Dermatology Department, Centre Hospitalo-Universitaire, Marseille, France
| | - E Gérard
- Dermatology Department, Centre Hospitalo-Universitaire, Bordeaux, France
| | | | - F Granel-Brocard
- Dermatology Department, Hôpitaux de Brabois Allée de Morvan, Vandoeuvre Les Nancy, France
| | - F Grange
- Dermatology Department, Centre Hospitalier, Valence, France
| | - T Jouary
- Dermatology Department, Hôpital François Mitterrand, Pau, France
| | - N Kramkimel
- Dermatology Department, Centre Hospitalo-Universitaire Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - C Lebbé
- Dermatology Department, Centre Hospitalo-Universitaire Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Y Le Corre
- Dermatology Department, Centre Hospitalo-Universitaire Angers, France
| | - D Legoupil
- Dermatology Department, Centre Hospitalo-Universitaire Régional, Brest, France
| | - C Lesage
- Dermatology Department, Hôpital Saint Eloi, Montpellier, France
| | | | - J-M Lorphelin
- Dermatology Department, Centre Hospitalo-Universitaire, Caen, France
| | - S Mansard
- Dermatology Department, Centre Hospitalo-Universitaire, Clermont Ferrand, France
| | - L Martin
- Dermatology Department, Centre Hospitalo-Universitaire, Angers, France; Groupe Ethique de la Société Française de Dermatologie, France
| | - S Mary-Prey
- Centre Hospitalo-Universitaire Saint André, Bordeaux, France
| | - E Maubec
- Dermatology Department, Centre Hospitalo-Universitaire Avicenne, Assistance Publique-Hôpitaux de Paris, Bobigny, France
| | - N Meyer
- Institut Universitaire du Cancer et Centre Hospitalo-Universitaire, Toulouse, France
| | - C Mignard
- Dermatology Department, Centre Hospitalo-Universitaire, Rouen, France
| | - H Montaudie
- Dermatology Department, Centre Hospitalier Universitaire de Nice, Université Côte d'Azur, Nice, France; INSERM U1065, Team 12, Centre Méditerranéen de Médecine Moléculaire, Université Nice Côte d'Azur, Nice, France
| | - L Mortier
- Dermatology Department, Centre Hospitalier Régional Universitaire, Lille, France
| | - C Nardin
- Université de Bourgogne-Franche-Comté et Centre Hospitalier Universitaire, Besançon, France; IINSERM UMR RIGHT 1098, Besançon, France
| | | | - C Pagès Laurent
- Institut Universitaire du Cancer et Centre Hospitalo-Universitaire, Toulouse, France
| | - L Peuvrel
- Medical Oncology Department, Institut de Cancérologie de l'Ouest, Saint Herblain, France
| | - Gaelle Quereux
- Dermatology Department, Centre Hospitalo-Universitaire, Nantes Université, Nantes, France; INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Nantes, France
| | - Caroline Robert
- Dermatology Department, Institut Gustave Roussy, Villejuif, France
| | - Philippe Saiag
- Dermatology Department, Centre Hospitalo-Universitaire Ambroise Paré, Assistance Publique-Hôpitaux de Paris, Boulogne Billancourt, France
| | - Mélanie Saint-Jean
- Medical Oncology Department, Institut de Cancérologie de l'Ouest, Saint Herblain, France
| | - M Samimi
- Dermatology Department, Centre Hospitalo-Universitaire, Tours, France
| | - B Sassolas
- Institute of Oncology & Hematology, Hôpital Morvan, Centre Hospitalier Régional Universitaire, Brest, France
| | - C Scalbert
- Dermatology Department, Centre Hospitalier Ouest Réunion, Saint Paul, Ile de la Réunion, France
| | - F Skowron
- Dermatology Department, Hôpitaux Drome Nord, Romans Sur Isère, France
| | - M Steff
- Dermatology Department, Centre Hospitalier Intercommunal Robert Ballanger, Aulnay sous-Bois, France
| | - P-E Stoebner
- Dermatology Department, Centre Hospitalo-Universitaire, Nîmes, France
| | - S Trablesi
- Dermatology Department, Centre Hospitalo-Universitaire, Grenoble, France
| | - L Visseaux
- Polyclinique Reims Bezannes, Bezannes, France
| | - O Zehou
- Dermatology Department, Centre Hospitalo-Universitaire Henri Mondor, Assistance Publique-Hôpitaux de Paris, Créteil, France
| | - A Boespflug
- Dermatology Department, Centre Hospitalier Henri Mondor, Villejuif, France
| |
Collapse
|
4
|
Cheuvart B, Callegaro A, Rosillon D, Meyer N, Guignard A. Effectiveness of maternal immunisation with a three-component acellular pertussis vaccine at preventing pertussis in infants in the United States: Post-hoc analysis of a case-control study using Bayesian dynamic borrowing. Vaccine 2023; 41:5805-5812. [PMID: 37635001 DOI: 10.1016/j.vaccine.2023.07.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2023] [Revised: 07/25/2023] [Accepted: 07/25/2023] [Indexed: 08/29/2023]
Abstract
BACKGROUND Immunisation during pregnancy with a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine can protect infants against pertussis between birth and paediatric vaccination. We aimed to estimate the vaccine effectiveness (VE) of third-trimester pregnancy immunisation with the three-component acellular pertussis (Td3ap) vaccine at preventing pertussis in infants <2 months in the United States (US), to support a label update. METHODS We performed a post-hoc sub-analysis of a case-control study conducted in six US Emerging Infections Program Network states between 2011 and 2014. Our analysis included only cases and controls whose mothers were either vaccinated with Td3ap or did not receive any Tdap vaccine. The association between Td3ap maternal immunisation and pertussis in infants was assessed for US data using a frequentist method with conditional logistic regression. A robustified analysis was conducted using Bayesian dynamic borrowing of non-US data, considering a mixing-weighted prior of 90% for historical non-US VE data, and of 10% for a vague prior. VE was estimated as (1-odds ratio) × 100%. Sensitivity analyses accounting for the impact of each non-US study, different mixing weights and missing/ambiguous data were performed. RESULTS We included 108 cases and 183 controls. Based on US data, the estimated VE of third-trimester maternal immunisation with Td3ap at preventing pertussis in infants <2 months was 78.0% (95% confidence interval: -38.0; 96.5). VE estimated by Bayesian dynamic borrowing of non-US data (with a 90% weight for historical data) was 83.4% (95% credible interval: 55.7; 92.5); sensitivity analyses produced similar VE estimates. CONCLUSIONS Effectiveness of third-trimester pregnancy immunisation with Td3ap at preventing infant pertussis in the US is very likely to be ≥ 50% and is most likely ∼ 80%. Bayesian dynamic borrowing of non-US VE data allowed overcoming the limited power (due to small sample size) of a brand-specific sub-analysis by considering additional evidence.
Collapse
Affiliation(s)
| | | | | | - Nadia Meyer
- GSK, Avenue Fleming 20, 1300 Wavre, Belgium.
| | | |
Collapse
|
5
|
Toulemonde E, Chevret S, Battistella M, Neidhardt EM, Nardin C, Le Du F, Meyer N, Véron M, Gambotti L, Lamrani-Ghaouti A, Jamme P, Chaffaut C, De Pontville M, Saada-Bouzid E, Beylot-Barry M, Simon C, Jouary T, Marabelle A, Mortier L. Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas. Cancer Immunol Immunother 2023:10.1007/s00262-023-03449-9. [PMID: 37067554 DOI: 10.1007/s00262-023-03449-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2022] [Accepted: 04/06/2023] [Indexed: 04/18/2023]
Abstract
Trichoblastic carcinoma is a rare malignant cutaneous adnexal tumor with a risk of local invasion and distant metastasis. As of today, there is no consensus for the treatment of locally advanced or metastatic trichoblastic carcinoma. "AcSé Nivolumab" is a multi-center Phase II basket clinical trial (NCT03012581) evaluating the safety and efficacy of nivolumab in several cohorts of rare, advanced cancers. Here we report the results of nivolumab in patients with trichoblastic carcinoma. Of the eleven patients enrolled in the study, five patients had been previously treated by sonic hedgehog inhibitors. The primary endpoint 12-week objective response rate was 9.1% (N = 1/11) with 1 partial response. Six patients who progressed under previous lines of treatment showed stable disease at 12 weeks, reflecting a good control of the disease with nivolumab. Furthermore, 54.5% of the patients (N = 6/11) had their disease under control at 6 months. The 1-year overall survival was 80%, and the median progression-free survival was 8.4 months (95%CI, 5.7 to NA). With 2 responders (2 complete responses), the best response rate to nivolumab at any time was 18.2% (95%CI, 2.3-51.8%). No new safety signals were identified, and adverse events observed herein were previously described and well known with nivolumab monotherapy. These results are promising, suggesting that nivolumab might be an option for patients with advanced trichoblastic carcinomas. Further studies on larger cohorts are necessary to confirm these results and define the role of nivolumab in the treatment of trichoblastic carcinomas.
Collapse
Affiliation(s)
- E Toulemonde
- Department of Dermatology, Claude Huriez Hospital, CHU de Lille, Lille, France.
| | - S Chevret
- Department of Biostatistics, Saint Louis Hospital, AP-HP, Paris, France
| | - M Battistella
- Department of Pathology, Saint Louis Hospital, AP-HP, Université Paris Cité, INSERM U976, Paris, France
- CARADERM Network, Lille, France
| | - E M Neidhardt
- Department of Oncology, Centre Léon Berard, Lyon, France
| | - C Nardin
- Department of Dermatology, CHU Besançon and INSERM 1098, Besançon, France
| | - F Le Du
- Department of Oncology, CLCC Eugène Marquis, Rennes, France
| | - N Meyer
- Department of Oncodermatology, IUC and CHU Toulouse, Toulouse, France
| | - M Véron
- Department of Dermatology, Claude Huriez Hospital, CHU de Lille, Lille, France
| | - L Gambotti
- Department of Clinical Research, Institut National Contre Le Cancer (INCa), Paris, France
| | | | - P Jamme
- Department of Dermatology, Claude Huriez Hospital, CHU de Lille, Lille, France
| | - C Chaffaut
- Department of Biostatistics, Saint Louis Hospital, AP-HP, Paris, France
| | - M De Pontville
- Department of Dermatology, CHU Caen, Caen, France
- CARADERM Network, Lille, France
| | - E Saada-Bouzid
- Department of Medical Oncology, Centre Antoine Lacassagne, Côte d'Azur University, Nice, France
| | - M Beylot-Barry
- Department of Dermatology, CHU Bordeaux, INSERM U1312, Bordeaux, France
- CARADERM Network, Lille, France
| | - C Simon
- Département R&D Unicancer, Paris, France
| | - T Jouary
- Department of Dermatology, François Mitterrand Hospital, Pau, France
- CARADERM Network, Lille, France
| | - A Marabelle
- Department of Therapeutic Innovations and Early Clinical Trials, INSERM U1015 & CIC1428, University of Paris Saclay, Gustave Roussy, Villejuif, France
| | - L Mortier
- Department of Dermatology, Claude Huriez Hospital, CARADERM and University of Lille, U1189 Inserm, 59000, Lille, France
- CARADERM Network, Lille, France
| |
Collapse
|
6
|
Meyer N, Vu TH, Brodowski L, Schröder-Heurich B, von Kaisenberg C, von Versen-Höynck F. Fetal endothelial colony-forming cell impairment after maternal kidney transplantation. Pediatr Res 2023; 93:810-817. [PMID: 35732823 PMCID: PMC10033415 DOI: 10.1038/s41390-022-02165-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2021] [Revised: 05/17/2022] [Accepted: 06/04/2022] [Indexed: 11/09/2022]
Abstract
BACKGROUND Successful pregnancies are nowadays possible after kidney transplantation but are associated with a higher incidence of maternal and fetal complications. Immunosuppressive therapy causes cardiovascular side effects but must be maintained during pregnancy. Little is known about the consequences of maternal kidney transplantation on offspring's endothelial health. Endothelial colony forming cells (ECFCs) represent a highly proliferative subtype of endothelial progenitor cells and are crucial for vascular homeostasis, repair and neovascularization. Therefore, we investigated whether maternal kidney transplantation affects fetal ECFCs' characteristics. METHODS ECFCs were isolated from umbilical cord blood of uncomplicated and post-kidney-transplant pregnancies and analyzed for their functional abilities with proliferation, cell migration, centrosome orientation and angiogenesis assays. Further, ECFCs from uncomplicated pregnancies were exposed to either umbilical cord serum from uncomplicated or post-kidney-transplant pregnancies. RESULTS Post-kidney-transplant ECFCs showed significantly less proliferation, less migration and less angiogenesis compared to control ECFCs. The presence of post-kidney-transplant umbilical cord serum led to similar functional aberrations of ECFCs from uncomplicated pregnancies. CONCLUSIONS These pilot data demonstrate differences in ECFCs' biological characteristics in offspring of women after kidney transplantation. Further studies are needed to monitor offspring's long-term cardiovascular development and to assess possible causal relationships with immunosuppressants, uremia and maternal cardiovascular alterations. IMPACT Pregnancy after kidney transplantation has become more common in the past years but is associated with higher complications for mother and offspring. Little is known of the impact of maternal kidney transplantation and the mandatory immunosuppressive therapy on offspring vascular development. In this study we are the first to address and detect an impairment of endothelial progenitor cell function in offspring of kidney-transplanted mothers. Serum from post-transplant pregnancies also causes negative effects on ECFCs' function. Clinical studies should focus on long-term monitoring of offspring's cardiovascular health.
Collapse
Affiliation(s)
- Nadia Meyer
- Gynecology Research Unit, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625, Hannover, Germany
| | - Thu Huong Vu
- Gynecology Research Unit, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625, Hannover, Germany
- Department of Obstetrics and Gynecology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625, Hannover, Germany
| | - Lars Brodowski
- Gynecology Research Unit, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625, Hannover, Germany
- Department of Obstetrics and Gynecology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625, Hannover, Germany
| | - Bianca Schröder-Heurich
- Gynecology Research Unit, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625, Hannover, Germany
| | - Constantin von Kaisenberg
- Department of Obstetrics and Gynecology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625, Hannover, Germany
| | - Frauke von Versen-Höynck
- Gynecology Research Unit, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625, Hannover, Germany.
- Department of Obstetrics and Gynecology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625, Hannover, Germany.
| |
Collapse
|
7
|
Florea A, Sy LS, Ackerson BK, Qian L, Luo Y, Becerra-Culqui T, Lee GS, Tian Y, Zheng C, Bathala R, Tartof SY, Campora L, Ceregido MA, Kuznetsova A, Poirrier JE, Rosillon D, Valdes L, Cheuvart B, Mesaros N, Meyer N, Guignard A, Tseng HF. Investigating Tetanus, Diphtheria, Acellular Pertussis Vaccination During Pregnancy and Risk of Congenital Anomalies. Infect Dis Ther 2023; 12:411-423. [PMID: 36520325 PMCID: PMC9925651 DOI: 10.1007/s40121-022-00731-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Accepted: 11/14/2022] [Indexed: 12/23/2022] Open
Abstract
INTRODUCTION This observational retrospective matched cohort study evaluated the safety of a prenatal tetanus, diphtheria, acellular pertussis (Tdap) vaccination, Boostrix. We previously reported on the risk of maternal and neonatal outcomes; here we report on the risk of congenital anomalies in infants at birth through 6 months of age. METHODS The study included pregnant Kaiser Permanente Southern California members. Women who received the Tdap vaccine on or after the 27th week of pregnancy between January 2018 and January 2019 were matched to women who were pregnant between January 2012 and December 2014 and were not vaccinated with Tdap during pregnancy. Unadjusted and adjusted relative risks (aRRs) with 95% confidence intervals were estimated by Poisson regression. Quantitative secular trend analyses, from 2011 to 2017, were conducted on congenital anomalies with a statistically significant aRR > 1. RESULTS The analysis consisted of 16,350 and 16,088 live-born infants in the Tdap-exposed and unexposed cohorts, respectively. Of the 14 congenital anomaly body systems evaluated, 8 (eye, ear/face/neck, respiratory, upper gastrointestinal, genital, renal, musculoskeletal, integument) had statistically significant elevated aRRs, with point estimates ranging from 1.17 to 2.02. The observed elevated aRRs were consistent with their respective secular increases over time. CONCLUSION Cautious interpretation of these findings is warranted as these increases may have resulted from improved identification and diagnosis. Furthermore, the biological plausibility of an association between maternal vaccine exposure in the third trimester of pregnancy and birth defects is low. The overall study findings support the safety of maternal immunization with Boostrix during the third trimester of pregnancy. TRIAL REGISTRATION ClinicalTrials.gov identifier, NCT03463577.
Collapse
Affiliation(s)
- Ana Florea
- Department of Research and Evaluation, Southern California Permanente Medical Group, Kaiser Permanente Southern California, Kaiser Permanente, 100 S Los Robles Ave, 2nd Floor, Pasadena, CA, 91101, USA.
| | - Lina S Sy
- Department of Research and Evaluation, Southern California Permanente Medical Group, Kaiser Permanente Southern California, Kaiser Permanente, 100 S Los Robles Ave, 2nd Floor, Pasadena, CA, 91101, USA
| | - Bradley K Ackerson
- Pediatrics and Pediatric Infectious Diseases, Southern California Permanente Medical Group, Harbor City, CA, USA
| | - Lei Qian
- Department of Research and Evaluation, Southern California Permanente Medical Group, Kaiser Permanente Southern California, Kaiser Permanente, 100 S Los Robles Ave, 2nd Floor, Pasadena, CA, 91101, USA
| | - Yi Luo
- Department of Research and Evaluation, Southern California Permanente Medical Group, Kaiser Permanente Southern California, Kaiser Permanente, 100 S Los Robles Ave, 2nd Floor, Pasadena, CA, 91101, USA
| | - Tracy Becerra-Culqui
- Department of Research and Evaluation, Southern California Permanente Medical Group, Kaiser Permanente Southern California, Kaiser Permanente, 100 S Los Robles Ave, 2nd Floor, Pasadena, CA, 91101, USA
- Department of Occupational Therapy, California State University, Dominguez Hills, Carson, CA, USA
| | - Gina S Lee
- Department of Research and Evaluation, Southern California Permanente Medical Group, Kaiser Permanente Southern California, Kaiser Permanente, 100 S Los Robles Ave, 2nd Floor, Pasadena, CA, 91101, USA
| | - Yun Tian
- Department of Research and Evaluation, Southern California Permanente Medical Group, Kaiser Permanente Southern California, Kaiser Permanente, 100 S Los Robles Ave, 2nd Floor, Pasadena, CA, 91101, USA
- Pharmaceutical Product Development, Thermo Fisher Scientific, Wilmington, NC, USA
| | - Chengyi Zheng
- Department of Research and Evaluation, Southern California Permanente Medical Group, Kaiser Permanente Southern California, Kaiser Permanente, 100 S Los Robles Ave, 2nd Floor, Pasadena, CA, 91101, USA
| | - Radha Bathala
- Department of Research and Evaluation, Southern California Permanente Medical Group, Kaiser Permanente Southern California, Kaiser Permanente, 100 S Los Robles Ave, 2nd Floor, Pasadena, CA, 91101, USA
| | - Sara Y Tartof
- Department of Research and Evaluation, Southern California Permanente Medical Group, Kaiser Permanente Southern California, Kaiser Permanente, 100 S Los Robles Ave, 2nd Floor, Pasadena, CA, 91101, USA
- Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA
| | | | | | | | | | | | | | | | - Narcisa Mesaros
- GSK Vaccines, Wavre, Belgium
- The Janssens Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium
| | | | | | - Hung-Fu Tseng
- Department of Research and Evaluation, Southern California Permanente Medical Group, Kaiser Permanente Southern California, Kaiser Permanente, 100 S Los Robles Ave, 2nd Floor, Pasadena, CA, 91101, USA
- Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA
| |
Collapse
|
8
|
Meyer N, Richter K, Brodowski L, von Kaisenberg C, Melk A, Schmidt B, Limbourg FP, Schröder-Heurich B, von Versen-Höynck F. Impairment of endothelial progenitor cells in women after kidney transplantation. Microcirculation 2023; 30:e12794. [PMID: 36484638 DOI: 10.1111/micc.12794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2022] [Revised: 11/04/2022] [Accepted: 12/06/2022] [Indexed: 12/13/2022]
Abstract
OBJECTIVE The long-term survival of kidney transplant patients has substantially improved. However, there is a higher risk for cardiovascular events after transplantation, partly due to immunosuppression. A diminished number of endothelial progenitor cells (EPCs), which play an important role in angiogenesis and the repair of endothelial damage, are associated with an increased cardiovascular risk. The aim of this study was to evaluate whether kidney transplantation affects EPCs in women. METHODS Twenty-four healthy women and 22 female kidney transplant recipients were recruited. The ratio of angiogenic and non-angiogenic circulating progenitor cells (CPCs) was determined by multicolor flow cytometry and related to clinical parameters. Cord blood-derived endothelial colony-forming cells (ECFCs), a proliferative subgroup of endothelial progenitor cells, were treated with pooled sera from transplant patients or healthy controls and tested for their functional integrity using in vitro models. RESULTS Kidney transplant recipients displayed a reduced ratio of angiogenic and non-angiogenic CPCs compared to healthy controls. Differences were especially pronounced in premenopausal women. Exposure to sera of transplanted women led to a significant impairment of ECFC proliferation, migration, and angiogenesis ability. CONCLUSIONS Alterations of EPC populations may contribute to the higher cardiovascular risks after organ transplantation and should be considered in therapeutic strategies.
Collapse
Affiliation(s)
- Nadia Meyer
- Gynecology Research Unit, Hannover Medical School, Hannover, Germany
| | - Katja Richter
- Gynecology Research Unit, Hannover Medical School, Hannover, Germany
| | - Lars Brodowski
- Gynecology Research Unit, Hannover Medical School, Hannover, Germany.,Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany
| | | | - Anette Melk
- Children's Hospital, Hannover Medical School, Hannover, Germany
| | - Bernhard Schmidt
- Department of Nephrology, Hannover Medical School, Hannover, Germany
| | - Florian P Limbourg
- Department of Nephrology, Vascular Medicine Research, Hannover Medical School, Hannover, Germany
| | | | - Frauke von Versen-Höynck
- Gynecology Research Unit, Hannover Medical School, Hannover, Germany.,Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany
| |
Collapse
|
9
|
Schorling D, Kölbel H, Hentschel A, Pechmann A, Meyer N, Wirth B, Rombo R, Consortium ASMA, Sickmann A, Kirschner J, Schara-Schmidt U, Lochmüller H, Roos A. VP.20 Cathepsin D as biomarker in CSF of nusinersen-treated patients with spinal muscular atrophy. Neuromuscul Disord 2022. [DOI: 10.1016/j.nmd.2022.07.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
10
|
Lier S, Rein I, Lund S, Lång A, Lång E, Meyer N, Dutta A, Anand S, Nesse G, Johansen R, Klungland A, Rinholm J, Bøe S, Anand A, Pollard S, Lerdrup M, Pandey D. P10.12.A CDK12/CDK13 inhibition disrupts a transcriptional program critical for glioblastoma survival. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac174.177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Glioblastoma multiforme (GBM) is the most prevalent and aggressive malignant tumor of the central nervous system. With a median survival of only one year, GBM patients have a particularly poor prognosis, highlighting a clear need for novel therapeutic strategies to target this disease. Transcriptional cyclin-dependent kinases (CDK), which phosphorylate key residues of RNA polymerase II (RNAPII) C-terminal domain (CTD), play a major role in sustaining aberrant transcriptional programs that are key to development and maintenance of cancer cells.
Material and Methods
We used pharmacological inhibition and genetic ablation to study effects of CDK12/CDK13 depletion on the proliferatory and migratory capacity of GBM cells and mouse xenografts. SLAM-seq, CUT&RUN and cell cycle assays were used to study the mechanistic effects of CDK12/CDK13 depletion in GBM cells.
Results
CDK12/CDK13 depletion markedly reduced the proliferatory and migratory capacity of GBM cells, as well as in vivo growth. CDK12/CDK13 inhibition potentiated existing chemotherapeutic treatments. Mechanistically, inhibition of CDK12/CDK13 leads to a genome-wide abrogation of RNAPII CTD phosphorylation, which in turn disrupts transcription and cell cycle progression in GBM cells.
Conclusion
These results provide proof-of-concept for the potential of CDK12 and CDK13 as therapeutic targets for GBM.
Collapse
Affiliation(s)
- S Lier
- Institute of Basic Medical Sciences, University of Oslo , Oslo , Norway
- Dept. of Microbiology, Oslo University Hospital , Oslo , Norway
| | - I Rein
- Dept. of Radiation Biology, Oslo University Hospital , Oslo , Norway
| | - S Lund
- Dept. of Microbiology, Oslo University Hospital , Oslo , Norway
| | - A Lång
- Dept. of Microbiology, Oslo University Hospital , Oslo , Norway
| | - E Lång
- Dept. of Microbiology, Oslo University Hospital , Oslo , Norway
| | - N Meyer
- Institute of Basic Medical Sciences, University of Oslo , Oslo , Norway
- Dept. of Microbiology, Oslo University Hospital , Oslo , Norway
| | - A Dutta
- Dept. of Computer Science and Engineering, Indian Institute of Technology, Guwahati , Assam , India
| | - S Anand
- Department of Informatics, Systems and Communications, University of Milano-Bicocca , Milan , Italy
| | - G Nesse
- Dept. of Microbiology, Oslo University Hospital , Oslo , Norway
| | - R Johansen
- Dept. of Microbiology, Oslo University Hospital , Oslo , Norway
| | - A Klungland
- Dept. of Microbiology, Oslo University Hospital , Oslo , Norway
- Dept. of Biosciences, University of Oslo , Oslo , Norway
| | - J Rinholm
- Institute of Basic Medical Sciences, University of Oslo , Oslo , Norway
- Dept. of Microbiology, Oslo University Hospital , Oslo , Norway
| | - S Bøe
- Dept. of Microbiology, Oslo University Hospital , Oslo , Norway
| | - A Anand
- Dept. of Computer Science and Engineering, Indian Institute of Technology, Guwahati , Assam , India
| | - S Pollard
- MRC Centre for Regenerative Medicine, SCRM Building, University of Edinburgh , Edinburgh , United Kingdom
| | - M Lerdrup
- Center for Chromosome Stability (CCS), Department of Cellular and Molecular Medicine, University of Copenhagen , Copenhagen , Denmark
| | - D Pandey
- Dept. of Microbiology, Oslo University Hospital , Oslo , Norway
| |
Collapse
|
11
|
Molinier O, Falchero L, Monnet I, Decroisette C, Neidhart AC, Redureau E, Chiappa AM, Bigot F, Bedossa A, Amrane K, Jeandeau S, Dujon C, Bugnet AS, Bonnefoy P, Alizon C, Meyer N, Couraud S, Cortot A, Letierce A, Debieuvre D. 509P COVID-19 disease among lung cancer (LC) patients: Data from a real-life prospective multicentric study. Ann Oncol 2022. [PMCID: PMC9472519 DOI: 10.1016/j.annonc.2022.07.637] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
12
|
Virazels M, Montfort A, Lusque A, Filleron T, Colacios C, Ségui B, Meyer N. 853P TNF plasma levels in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
13
|
Meyer N, Lusque A, Virazels M, Filleron T, Colacios C, Montfort A, Ségui B. 846P Triple combination of ipilimumab + nivolumab + anti-TNF in treatment naive melanoma patients: Final analysis of TICIMEL, a phase Ib prospective clinical trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
14
|
Tseng HF, Sy LS, Ackerson BK, Lee GS, Luo Y, Florea A, Becerra-Culqui T, Tartof SY, Tian Y, Taylor C, Campora L, Ceregido MA, Kuznetsova A, Poirrier JE, Rosillon D, Valdes L, Cheuvart B, Mesaros N, Meyer N, Guignard A, Qian L. Safety of tetanus, diphtheria, acellular pertussis (Tdap) vaccination during pregnancy. Vaccine 2022; 40:4503-4512. [PMID: 35717267 DOI: 10.1016/j.vaccine.2022.06.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2021] [Revised: 05/27/2022] [Accepted: 06/02/2022] [Indexed: 10/18/2022]
Abstract
The objective of this study was to evaluate the safety of prenatal tetanus, diphtheria, acellular pertussis (Tdap) vaccination. This cohort study was conducted among pregnant members at Kaiser Permanente Southern California (KPSC). The exposed cohort consisted of women who received Tdap vaccine on or after the 27th week of pregnancy between January 2018 and January 2019. The unexposed cohort consisted of matched women who were pregnant between January 2012 and December 2014 and were not vaccinated with any Tdap vaccine throughout their pregnancy. Maternal and infant characteristics and pre-specified endpoints were collected through automated data and review of the electronic health records. Unadjusted and adjusted relative risks (aRRs) with confidence intervals (CIs) were estimated by Poisson regression. Non-inferiority testing (i.e., to rule out a two-fold increase) was conducted for primary endpoints with adjustment for multiplicity. Superiority testing was conducted without multiplicity adjustment for secondary endpoints. The analysis consisted of 16,606 pairs of Tdap recipients and unexposed pregnant women. For the primary endpoints, the aRR for preeclampsia/eclampsia was 1.38 (98.75% CI:1.21-1.58) and the aRR for intrauterine infection was 1.28 (98.75% CI:1.12-1.47). These increases were consistent with the background increasing trend of these diagnoses among all pregnant women at KPSC since 2011, and the upper limit of the 98.75% CI of both aRRs did not exceed the pre-specified threshold of 2. No increased risks of small for gestational age (aRR = 1.04, 98.75% CI:0.94-1.16) or preterm delivery (aRR = 0.71, 98.75% CI:0.64-0.78) were observed. No evidence of increased risks for secondary endpoints, including poor fetal growth, preterm pre-labor rupture of membranes, stillbirth/fetal death, placental abruption, transfusion during delivery hospitalization, and neonatal death, was observed. Prenatal Tdap vaccination after the 27th week of pregnancy was not associated with increased risks of pre-specified maternal and infant outcomes, supporting the safety of Tdap vaccination during pregnancy.
Collapse
Affiliation(s)
- Hung Fu Tseng
- Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USA.
| | - Lina S Sy
- Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.
| | - Bradley K Ackerson
- Pediatrics and Pediatric Infectious Diseases, Southern California Permanente Medical Group, Harbor City, CA, USA
| | - Gina S Lee
- Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA
| | - Yi Luo
- Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA
| | - Ana Florea
- Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA
| | - Tracy Becerra-Culqui
- Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA
| | - Sara Y Tartof
- Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA
| | - Yun Tian
- Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA
| | - Christine Taylor
- Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA
| | | | | | | | | | | | | | | | | | | | | | - Lei Qian
- Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA
| |
Collapse
|
15
|
Hughes BGM, Munoz-Couselo E, Mortier L, Bratland Å, Gutzmer R, Roshdy O, González Mendoza R, Schachter J, Arance A, Grange F, Meyer N, Joshi A, Billan S, Zhang P, Gumuscu B, Swaby RF, Grob JJ. Corrigendum to 'Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285]. Ann Oncol 2022; 33:853. [PMID: 35690517 DOI: 10.1016/j.annonc.2022.05.517] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- B G M Hughes
- Cancer Care Services, Royal Brisbane and Women's Hospital, Herston; University of Queensland, Brisbane, Australia.
| | - E Munoz-Couselo
- Hospital Vall D Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | - L Mortier
- University of Lille, Inserm U 1189, CHU Lille, Lille, France
| | | | - R Gutzmer
- Department of Dermatology and Allergy, Skin Cancer Center Hannover, Medizinische Hochschule Hannover, Hanover; Mühlenkreiskliniken, Ruhr University Bochum Campus Minden, Minden, Germany
| | - O Roshdy
- Jewish General Hospital, Montreal, Canada
| | | | - J Schachter
- Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, Israel
| | - A Arance
- Hospital Clínic i Provincial de Barcelona, Barcelona, Spain
| | - F Grange
- Dermatology Department, Center Hospitalier Universitaire de Reims-Hôpital Robert Debre, Reims
| | - N Meyer
- Dermatology, Institut Universitaire du Cancer and CHU de Toulouse, Toulouse, France
| | - A Joshi
- Department of Medical Oncology, Townsville University Hospital, Townsville, Australia
| | - S Billan
- The Head and Neck Center, Oncology Department, Rambam Health Care Campus, Haifa, Israel
| | - P Zhang
- Merck & Co., Inc., Kenilworth, USA
| | | | | | - J-J Grob
- Service de Dermatologie et Cancérologie Cutanée, Aix-Marseille University, Marseille, France
| |
Collapse
|
16
|
Schröder-Heurich B, Büder T, Meyer N, Vu TH, Richter K, Ramachandran D, Brodowski L, von Kaisenberg CS, von Versen-Höynck F. Downregulation of miR-1270 mediates endothelial progenitor cell function in preeclampsia: Role for ATM in the Src/VE-cadherin axis. FASEB J 2022; 36:e22379. [PMID: 35648632 DOI: 10.1096/fj.202200040rr] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Revised: 05/06/2022] [Accepted: 05/16/2022] [Indexed: 11/11/2022]
Abstract
Preeclampsia, a pregnancy-related hypertensive disorder, is associated with endothelial dysfunction and increased cardiovascular risk of the offspring in adulthood. In preeclampsia, endothelial colony-forming cells (ECFC) are reduced in number and function. Recently, we have shown that miR-1270, which is involved in cancer in vitro proliferation, migration, and tumor progression, is downregulated in fetal ECFC from preeclamptic pregnancies. We now hypothesize that miR-1270 dysregulation contributes to vascular endothelial dysfunction occurring after preeclampsia via ATM (ataxia telangiectasia mutated) overexpression, the key kinase of DNA damage repair. Here, we show that miR-1270 silencing in normal ECFC and downregulation in preeclamptic ECFC are accompanied by an increase in the expression levels of ATM. Furthermore, ATM activation correlates with upregulated tyrosine kinase Src leading to phosphorylation and internalization of VE-cadherin (vascular endothelial-cadherin) which subsequently compromises endothelial barrier permeability and morphodynamic cell parameters. Treatment with specific ATM inhibitors reveals a novel role of ATM upstream of tyrosine kinase Src activation. Subsequently, Src phosphorylation and internalization of VE-cadherin compromise endothelial barrier permeability. Our findings suggest that downregulation of miR-1270 contributes to impaired ECFC function via the associated ATM overexpression, which further identifies ATM as a novel and critical factor for ECFC defects in preeclampsia. Our study provides new insights into the understanding of ECFC impairment associated with cardiovascular risk in preeclamptic offspring and identifies potential novel therapeutic targets.
Collapse
Affiliation(s)
| | - Tim Büder
- Gynecology Research Unit, Hannover Medical School, Hannover, Germany
| | - Nadia Meyer
- Gynecology Research Unit, Hannover Medical School, Hannover, Germany
| | - Thu Huong Vu
- Gynecology Research Unit, Hannover Medical School, Hannover, Germany.,Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany
| | - Katja Richter
- Gynecology Research Unit, Hannover Medical School, Hannover, Germany
| | | | - Lars Brodowski
- Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany
| | | | - Frauke von Versen-Höynck
- Gynecology Research Unit, Hannover Medical School, Hannover, Germany.,Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany
| |
Collapse
|
17
|
ZHANG Y, Ghiringhelli Borsa N, Goodfellow R, Dunlop H, Meyer N, Shao D, Jones M, Pitcher G, Taylor A, Nester C, Smith R. POS-024 COMPLEMENT FACTOR I VARIANTS IN ATYPICAL HEMOLYTIC UREMIC SYNDROME AND C3 GLOMERULOPATHY. Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.04.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
18
|
HAUER J, Meyer N, Goodfellow R, Nester C, Zhang Y, Smith R. POS-017 A POPULATION PERSPECTIVE OF NEPHRITIC FACTORS AS SYSTEMIC DRIVERS OF COMPLEMENT DYSREGULATION IN C3 GLOMERULOPATHY. Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.04.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
19
|
Felten R, Fabacher T, Sedmak N, Berenbaum F, Combe B, Sibilia J, Sordet C, Chatelus E, Ruyssen-Witrand A, Vittecoq O, Meyer N, Gottenberg JE. POS0533 REPURPOSING FIB-4 SCORE IN RHEUMATOID ARTHRITIS: DATA FROM THE ESPOIR COHORT. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundThe Fibrosis-4 (FIB4) score, including age, transaminases and platelets, can detect severe fibrosis (F3-F4) in patients with Non Alcoolic Steato Hepatitis (NASH) and could be of interest in the follow-up of patients with RA. Indeed, platelets contribute to the pathophysiology of RA, transaminases are used in the liver monitoring of our treatments. In addition, retrospective data suggested the association between FIB4 and mortality in RA (1).ObjectivesWe aimed to evaluate the value of the FIB4 score as a prognostic factor in RA in the prospective ESPOIR cohort.MethodsPatients of the ESPOIR cohort diagnosed with RA according to ACR-EULAR criteria were included in our analysis. The formula for the FIB-4 score is as follows: [Age (years) × ASAT (U/L)] / [Platelet count (10^9/L) × ALT (U/L)1/2]. The analyses were based on linear mixed-effects models with a random effect on the subject to account for repeated measures throughout time.Results633 of the 813 patients included met the ACR/EULAR criteria for RA and had a calculable FIB4 score. Median FIB4 was 0.75 IQR (0.53-0.99) and 61 patients (9.6%) had a high FIB4 score at baseline. Baseline FIB4 was significantly higher in patients with a chronic alcohol consumption (p=0.021) or viral hepatitis (p<0.001). In multivariate analysis, including the main baseline prognostic factors for progression of RA (swollen Joint Count, CRP, Presence of ACPA, Rheumatoid Factor and modified Sharp score), FIB4 was not independently associated with progression of DAS28 during 10 years of follow-up, unlike baseline CRP and SJC. Baseline FIB4 was not associated with the modified Sharp score at 10-year follow-up unlike age and the presence of ACPA (Table 1). FIB4 was not associated with mortality (p=0.77) or major adverse cardiovascular events (p=0.22) during the 10-year follow-up. No significant change in FIB4 score over time was related to the use of NSAIDs, methotrexate, tocilizumab or other DMARDs.Table 1.Associations of FIB4 score with DAS28 and modified Sharp score evolutions in multivariate analysesVariableVariables included in modelp-valueDAS28Time<0.0001Age0.97Baseline number of swollen joints<0.0001Baseline Rheumatoid Factor0.51evolution over timeBaseline ACPA (presence)0.97Baseline CRP<0.0001Baseline modified Sharp score > 00.15Baseline FIB40.26Modified Sharp scoreTime0.052Age0.0005Baseline number of swollen joints0.38Baseline Rheumatoid Factor0.61evolution over timeBaseline ACPA (presence)0.012Baseline CRP0.84Baseline FIB40.25ConclusionOur study was the first to evaluate the value of FIB4 in a prospective cohort of RA patients. The present prospective cohort study with a 10-year follow-up did not find a prognostic role of FIB4 in RA, in contrast to previous retrospective studies. Reassuringly, FIB4 score was not increased by DMARD treatment after 10 years of follow-up, confirming the absence of long-term DMARD-related hepatotoxicity.References[1]Seung Up Kim, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong-Beom Park, Kwang-Hyub Han & Sang-Won Lee (2018): Fibrosis-4 index at diagnosis can predict all-cause mortality in patients with rheumatoid arthritis: A retrospective monocentric study, Modern Rheumatology, DOI: 10.1080/14397595.2018.1558760Figure 1.Impact of baseline FIB4 score on DAS28, HAQ and total modified-Sharp score over time.AcknowledgementsAn unrestricted grant from Merck Sharp and Dohme (MSD) was allocated for the first 5 years. Two additional grants from INSERM were obtained to support part of the biological database. The French Society of Rheumatology, Pfizer, Abbvie, Lilly, Sanofi also supported the ESPOIR cohort study.We also wish to thank Nathalie Rincheval (CHU Montpellier and EA 2415) who did expert monitoring and data management and all the investigators who recruited and followed the patients (F. Berenbaum, Paris-Saint Antoine, MC. Boissier, Paris-Bobigny, A. Cantagrel, Toulouse, B. Combe, Montpellier, M. Dougados, Paris-Cochin, P. Fardellone et P. Boumier Amiens, B. Fautrel, Paris-La Pitié, RM. Flipo, Lille, Ph. Goupille, Tours, F. Liote, Paris- Lariboisière, O. Vittecoq, Rouen, X. Mariette, Paris Bicetre, P. Dieude, Paris Bichat, A. Saraux, Brest, T. Schaeverbeke, Bordeaux, J. Sibilia, Strasbourg) V. Devauchelle and C Lukas for expert X-ray reading.Disclosure of InterestsNone declared.
Collapse
|
20
|
Calderón AP, Louvrier J, Planillo A, Araya‐Gamboa D, Arroyo‐Arce S, Barrantes‐Núñez M, Carazo‐Salazar J, Corrales‐Gutiérrez D, Doncaster CP, Foster R, García MJ, Garcia‐Anleu R, Harmsen B, Hernández‐Potosme S, Leonardo R, Trigueros DM, McNab R, Meyer N, Moreno R, Salom‐Pérez R, Sauma Rossi A, Thomson I, Thornton D, Urbina Y, Grimm V, Kramer‐Schadt S. Occupancy models reveal potential of conservation prioritization for Central American jaguars. Anim Conserv 2022. [DOI: 10.1111/acv.12772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- A P Calderón
- Department of Ecological Dynamics Leibniz Institute for Zoo and Wildlife Research Berlin Germany
- Department of Ecological Modelling Helmholtz Centre for Environmental Research – UFZ Leipzig Germany
- Plant Ecology and Nature Conservation University of Potsdam Potsdam Germany
| | - J Louvrier
- Department of Ecological Dynamics Leibniz Institute for Zoo and Wildlife Research Berlin Germany
- Department of Ecology Technische Universität Berlin Berlin Germany
| | - A Planillo
- Department of Ecological Dynamics Leibniz Institute for Zoo and Wildlife Research Berlin Germany
| | | | - S Arroyo‐Arce
- Coastal Jaguar Conservation Santo Domingo Heredia Costa Rica
| | | | | | | | - C P Doncaster
- School of Biological Sciences University of Southampton Southampton UK
| | | | - M J García
- Centro de Estudios Conservacionistas San Carlos University Guatemala Guatemala
| | | | - B Harmsen
- Panthera New York NY USA
- Environmental Research Institute University of Belize Belmopan Belize
| | | | - R Leonardo
- Centro de Estudios Conservacionistas San Carlos University Guatemala Guatemala
| | | | - R McNab
- Wildlife Conservation Society Flores Guatemala
| | - N Meyer
- Fundación Yaguará Panama Clayton Panama
- Conservation Science Research Group The University of Newcastle Callaghan New South Wales Australia
- Chair of Wildlife Ecology and Management Albert‐Ludwigs‐Universität Freiburg Freiburg Germany
| | - R Moreno
- Fundación Yaguará Panama Clayton Panama
- Smithsonian Tropical Research Institute Panamá City Panamá
| | | | | | - I Thomson
- Coastal Jaguar Conservation Santo Domingo Heredia Costa Rica
| | - D Thornton
- School of the Environment Washington State University Pullman WA USA
| | | | - V Grimm
- Department of Ecological Modelling Helmholtz Centre for Environmental Research – UFZ Leipzig Germany
- Plant Ecology and Nature Conservation University of Potsdam Potsdam Germany
| | - S Kramer‐Schadt
- Department of Ecological Dynamics Leibniz Institute for Zoo and Wildlife Research Berlin Germany
- Department of Ecology Technische Universität Berlin Berlin Germany
| |
Collapse
|
21
|
Salomon G, Severino M, Casassa E, Livideanu CB, Meyer N, Lamant L, Tournier E, Paul C. Skin manifestations of hypereosinophilic syndrome are polymorphous and difficult to treat: A retrospective cohort study. Ann Dermatol Venereol 2022; 149:139-141. [PMID: 35115205 DOI: 10.1016/j.annder.2021.12.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2021] [Revised: 07/21/2021] [Accepted: 12/22/2021] [Indexed: 11/19/2022]
Affiliation(s)
- G Salomon
- Dermatology, Paul Sabatier-Toulouse III University, Larrey Hospital, 31059 Toulouse cedex 9, France.
| | - M Severino
- Dermatology, Paul Sabatier-Toulouse III University, Larrey Hospital, 31059 Toulouse cedex 9, France
| | - E Casassa
- Dermatology, Paul Sabatier-Toulouse III University, Larrey Hospital, 31059 Toulouse cedex 9, France
| | - C Bulai Livideanu
- Dermatology, Paul Sabatier-Toulouse III University, Larrey Hospital, 31059 Toulouse cedex 9, France
| | - N Meyer
- Onco-Dermatology, University Institute of Cancer, University Hospital, 31100 Toulouse, France
| | - L Lamant
- Pathology, University Institute of Cancer, University Hospital, 31100 Toulouse, France
| | - E Tournier
- Pathology, University Institute of Cancer, University Hospital, 31100 Toulouse, France
| | - C Paul
- Dermatology, Paul Sabatier-Toulouse III University, Larrey Hospital, 31059 Toulouse cedex 9, France
| |
Collapse
|
22
|
Delbarre M, Hidalgo Diaz JJ, Xavier F, Meyer N, Sapa MC, Liverneaux P. Reduction in ionizing radiation exposure during minimally invasive anterior plate osteosynthesis of distal radius fracture: Naive versus deliberate practice. Hand Surg Rehabil 2021; 41:194-198. [PMID: 34920144 DOI: 10.1016/j.hansur.2021.12.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/23/2021] [Revised: 11/28/2021] [Accepted: 12/02/2021] [Indexed: 10/19/2022]
Abstract
This study aimed to decrease surgeon exposure to ionizing radiation through a new learning technique, "deliberate practice", which consists in improving performance by setting goals with feedback. The hypothesis was that exposure to ionizing radiation during distal radius fracture surgery using the minimally invasive plate osteosynthesis (MIPO) technique decreased faster with "deliberate" practice than with "naïve" practice. Radiographic dosimetry was measured in the first 30 fractures operated on by MIPO by 6 surgeons. The first 3 surgeons operated "naively" (Group 1) and the next 3 according to the "deliberate" procedure (Group 2). Group 2 received weekly feedback (number of exposed hands, number of fluoroscopic views, exposure duration, and X-ray dose). An expert, using fluoroscopic images and surgical videos, provided suggestions for improvement. Mean number of exposed hands was 23.66 in Group 1 and 1.9 in Group 2. Mean number of fluoroscopic views was 78.31 and 35.0, respectively. Mean X-ray exposure time was 74.34 and 32.89 s, respectively. Mean dosimetry was 1.40 mGy (and 0.59 mGy, respectively. The hypothesis was thus confirmed: dosimetry decreased faster in Group 2 than in Group 1. Teaching this deliberate practice should be generalized, to decrease the growth phase and increase the plateau phase of the learning curve.
Collapse
Affiliation(s)
- M Delbarre
- Department of Hand Surgery, Strasbourg University Hospitals, FMTS, 1 Avenue Molière, 67200 Strasbourg, France
| | - J J Hidalgo Diaz
- Department of Orthopedics, Centre Hospitalier Universitaire de Reims, Hôpital Maison Blanche, 45 Rue Cognacq Jay, 51100 Reims, France
| | - F Xavier
- Department of Pediatric Surgery, Brest University Hospitals, 2 Avenue Foch, 29200 Brest, France
| | - N Meyer
- Strasbourg University Hospital, Service de Santé Publique, GMRC, 1 Place de L'Hôpital, 67091 Strasbourg Cedex, France
| | - M-C Sapa
- Department of Hand Surgery, Strasbourg University Hospitals, FMTS, 1 Avenue Molière, 67200 Strasbourg, France
| | - P Liverneaux
- Department of Hand Surgery, Strasbourg University Hospitals, FMTS, 1 Avenue Molière, 67200 Strasbourg, France; ICube CNRS, UMR 7357, Strasbourg University, 2-4 Rue Boussingault, 67000 Strasbourg, France.
| |
Collapse
|
23
|
Comont T, Dion J, Baroudjian B, Ezine E, Careira C, Anderle A, Apalla Z, Freites-Martinez A, Meyer N, Sibaud V. Sarcoïdose induite par les inhibiteurs de BRAF-MEK : série rétrospective européenne. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.10.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
24
|
Munoz Couselo E, Hughes B, Bratland Å, Gutzmer R, Roshdy O, González Mendoza R, Schachter J, Arance Fernandez A, Grange F, Meyer N, Joshi A, Billan S, Grob J, Zhang P, Gumuscu B, Swaby R, Mortier L. 149P KEYNOTE-629: Efficacy of pembrolizumab (Pembro) per immune-related RECIST (irRECIST) in locally advanced (LA) and recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
25
|
Bassompierre A, Dalac S, Dreno B, Neidhardt EM, Maubec E, Capelle C, Andre F, Behal H, Dziwniel V, Bens G, Leccia MT, Meyer N, Granel-Brocard F, Beylot-Barry M, Dereure O, Basset-Seguin N, Mortier L. Efficacy of sonic hedgehog inhibitors rechallenge, after initial complete response in recurrent advanced basal cell carcinoma: a retrospective study from the CARADERM database. ESMO Open 2021; 6:100284. [PMID: 34689002 PMCID: PMC8551849 DOI: 10.1016/j.esmoop.2021.100284] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2021] [Revised: 09/12/2021] [Accepted: 09/22/2021] [Indexed: 11/01/2022] Open
Abstract
BACKGROUND Smoothened (SMO) inhibitors, blocking the sonic hedgehog pathway, have been approved for advanced basal cell carcinoma (aBCC). Safety analyses reveal a high rate of adverse events (AEs) and, most of the time, vismodegib is most commonly stopped when the best overall response is reached. The long-term evolution of aBCC after vismodegib discontinuation is poorly described. The aim of this study is to evaluate the efficacy and safety of the SMO inhibitors (SMOis) available (vismodegib and sonidegib) following rechallenge after complete response (CR) following an initial treatment by vismodegib. MATERIALS AND METHODS This real-life, retrospective, multicenter and descriptive study is based on an extraction from the CARADERM accredited database, including 40 French regional hospitals, of patients requiring BCC systemic treatment. RESULTS Of 303 patients treated with vismodegib, 110 achieved an initial CR. The vast majority of these patients (98.2%) stopped vismodegib, notably due to poorly tolerated AEs. The CARADERM database provided a median follow-up of 21 months (13.5-36.0 months) after CR. Of the 110 patients, 48.1% relapsed after a median relapse-free survival of 24 months (13.0-38.0 months). Among them, 35 patients were retreated by an SMOi and the overall response rate was 65.7% (34.3% of CR and 31.4% of partial response). The median duration of retreatment was 6.0 months (4.0-9.5 months). CONCLUSION Our real-life study, carried out on patients with complex clinical pictures, shows that after treatment discontinuation, 48.1% of patients achieved CR relapse within an average of 24 months (13.0-38.0 months). It emphasized that even though rechallenge can be considered as a therapeutic option, efficacy seems to decrease, suggesting the development of resistance mechanisms.
Collapse
Affiliation(s)
- A Bassompierre
- Department of Dermatology, Lille University, CHU Lille, Lille, France.
| | - S Dalac
- Department of Dermatology, Dijon University Hospital, Dijon, France
| | - B Dreno
- Department of Dermatology, Dieu Hospital, Nantes, France
| | - E M Neidhardt
- Department of Dermatology, Léon Bérard Center, Lyon, France
| | - E Maubec
- Department of Dermatology, AP-HP, Avicenne University Hospital, Bobigny, France
| | - C Capelle
- Department of Dermatology, Lille University, CHU Lille, Lille, France
| | - F Andre
- Department of Dermatology, Lille University, CHU Lille, Lille, France
| | - H Behal
- Health Technology and Medical Practice Assessment, ULR 2694-METRICS, Lille University Hospital, University of Lille, Lille, France
| | - V Dziwniel
- Department of Dermatology, Lille University, CHU Lille, Lille, France; Languages Department, Centrale Lille Institut, Villeneuve d'Ascq, France
| | - G Bens
- Department of Dermatology, Orleans Regional Hospital, Orleans, France
| | - M T Leccia
- Department of Dermatology, Grenoble University Hospital, Grenoble, France
| | - N Meyer
- Department of Dermatology, IUC and CHU de Toulouse, Toulouse, France
| | - F Granel-Brocard
- Department of Dermatology, Nancy University Hospital, Nancy, France
| | - M Beylot-Barry
- Department of Dermatology, Bordeaux University Hospital, Bordeaux, France
| | - O Dereure
- Department of Dermatology, University of Montpellier, Montpellier, France
| | - N Basset-Seguin
- Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris University Hospital, Paris, France
| | - L Mortier
- Department of Dermatology, Lille University, CHU Lille, Lille, France; INSERM U1189, CARADERM, CHU Lille, Lille, France
| |
Collapse
|
26
|
Sibaud V, Brun A, Meyer N, Oberic L, Lamant L, Ysebaert L. Efficacy of dupilumab in eosinophilic dermatosis of haematologic malignancy (EDHM) needs to be confirmed. J Eur Acad Dermatol Venereol 2021; 36:e213-e215. [PMID: 34657337 DOI: 10.1111/jdv.17748] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2021] [Revised: 09/17/2021] [Accepted: 10/15/2021] [Indexed: 11/26/2022]
Affiliation(s)
- V Sibaud
- Oncodermatology Department, Institut Claudius Regaud and Institut, Universitaire du Cancer Toulouse Oncopole, Toulouse, France
| | - A Brun
- Oncodermatology Department, Institut Claudius Regaud and Institut, Universitaire du Cancer Toulouse Oncopole, Toulouse, France
| | - N Meyer
- Oncodermatology Department, Institut Claudius Regaud and Institut, Universitaire du Cancer Toulouse Oncopole, Toulouse, France
| | - L Oberic
- Haematology Department, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
| | - L Lamant
- Pathology Department, Institut Claudius Regaud and Institut, Universitaire du Cancer Toulouse Oncopole, Toulouse, France
| | - L Ysebaert
- Haematology Department, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
| |
Collapse
|
27
|
Long G, Tawbi H, Meyer N, Breznen B, Vyas C, Leung L, Moshyk A, Pushkarna D, Thakkar P, Fazeli M, Kotapati S, Schadendorf D. 1077P Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) undergoing systemic therapy: A systematic literature review (SLR) and meta-analysis (MA) of real-world evidence (RWE). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
28
|
Grob J, Aubin F, Benmahammed-Bellagha L, Brunet-Possenti F, Dereure O, Dutriaux C, Duval-Modeste AB, Grange F, Jarvis C, Kramkimel N, Leccia MT, Machet L, Meyer N, Mortier L, Neidhardt EM, Robert C, Scherrer E, Spampinato A, Verdoni L, Saiag P. 1080P HORIZON: Final results from a 5-year ambispective study of 705 patients who initiated pembrolizumab for advanced melanoma in the French early access program. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
29
|
Brodowski L, Schröder-Heurich B, von Hardenberg S, Richter K, von Kaisenberg CS, Dittrich-Breiholz O, Meyer N, Dörk T, von Versen-Höynck F. MicroRNA Profiles of Maternal and Neonatal Endothelial Progenitor Cells in Preeclampsia. Int J Mol Sci 2021; 22:ijms22105320. [PMID: 34070163 PMCID: PMC8158476 DOI: 10.3390/ijms22105320] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2021] [Revised: 05/11/2021] [Accepted: 05/12/2021] [Indexed: 01/08/2023] Open
Abstract
Preeclampsia is associated with an increased cardiovascular morbidity of mother and offspring, thus contributing to a substantial burden in women and children’s health. It has been proven that endothelial progenitor cell (EPC) numbers and functional characteristics are impaired in cardiovascular disease and preeclampsia, although causative factors for the latter have remained elusive. MicroRNA (miRNA) modifications are a potential mechanism through which exposure to an altered environment translates into the development of chronic disease. In this study, we examined whether development of preeclampsia corresponds to alterations of miRNAs in maternal- and cord-blood-derived EPC. To test this end, we analyzed maternal and neonatal miRNAs via RNA sequencing from endothelial cells of preeclamptic and healthy controls in different cell culture passages. We were able to demonstrate differentially represented miRNAs in all groups. Hsa-miR-1270 showed significantly different levels in cord blood EPC from preeclampsia versus control and was negatively correlated with mRNA levels of its predicted targets ANGPTL7 and TFRC. Transfection with an hsa-miR-1270 inhibitor decreased the tube formation capacity and chemotactic motility but did not change proliferation in vitro. Target predictions and gene set enrichment analyses identified alternative splicing as a significantly enriched pathway for hsa-miR-1270. The top miRNAs in three other groups were predicted to target transcriptional and developmental pathways. Here, we showed for the first time significantly different levels of miRNAs and differently represented mRNA levels of predicted target genes in EPC derived from preeclampsia. Understanding the effects of preeclampsia on the epigenetic mechanisms of EPC will be crucial and may provide initial insights for further evaluation of the benefits of therapies targeting this cell population.
Collapse
Affiliation(s)
- Lars Brodowski
- Gynecology Research Unit, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany; (L.B.); (B.S.-H.); (S.v.H.); (K.R.); (N.M.); (T.D.)
- Department of Obstetrics and Gynecology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany;
| | - Bianca Schröder-Heurich
- Gynecology Research Unit, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany; (L.B.); (B.S.-H.); (S.v.H.); (K.R.); (N.M.); (T.D.)
| | - Sandra von Hardenberg
- Gynecology Research Unit, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany; (L.B.); (B.S.-H.); (S.v.H.); (K.R.); (N.M.); (T.D.)
| | - Katja Richter
- Gynecology Research Unit, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany; (L.B.); (B.S.-H.); (S.v.H.); (K.R.); (N.M.); (T.D.)
| | - Constantin S. von Kaisenberg
- Department of Obstetrics and Gynecology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany;
| | - Oliver Dittrich-Breiholz
- Research Core Unit Genomics, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany;
| | - Nadia Meyer
- Gynecology Research Unit, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany; (L.B.); (B.S.-H.); (S.v.H.); (K.R.); (N.M.); (T.D.)
| | - Thilo Dörk
- Gynecology Research Unit, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany; (L.B.); (B.S.-H.); (S.v.H.); (K.R.); (N.M.); (T.D.)
| | - Frauke von Versen-Höynck
- Gynecology Research Unit, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany; (L.B.); (B.S.-H.); (S.v.H.); (K.R.); (N.M.); (T.D.)
- Department of Obstetrics and Gynecology, Hannover Medical School, Carl-Neuberg-Strasse 1, D-30625 Hannover, Germany;
- Correspondence: ; Tel.: +49-511-532-8703; Fax: +49-511-532-6081
| |
Collapse
|
30
|
Chilengi R, Mwila-Kazimbaya K, Chirwa M, Sukwa N, Chipeta C, Velu RM, Katanekwa N, Babji S, Kang G, McNeal MM, Meyer N, Gompana G, Hazra S, Tang Y, Flores J, Bhat N, Rathi N. Immunogenicity and safety of two monovalent rotavirus vaccines, ROTAVAC® and ROTAVAC 5D® in Zambian infants. Vaccine 2021; 39:3633-3640. [PMID: 33992437 PMCID: PMC8204902 DOI: 10.1016/j.vaccine.2021.04.060] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2020] [Revised: 03/17/2021] [Accepted: 04/28/2021] [Indexed: 02/03/2023]
Abstract
BACKGROUND AND AIMS ROTAVAC® (frozen formulation stored at -20 °C) and ROTAVAC 5D® (liquid formulation stable at 2-8 °C) are rotavirus vaccines derived from the 116E human neonatal rotavirus strain, developed and licensed in India. This study evaluated and compared the safety and immunogenicity of these vaccines in an infant population in Zambia. METHODS We conducted a phase 2b, open-label, randomized, controlled trial wherein 450 infants 6 to 8 weeks of age were randomized equally to receive three doses of ROTAVAC or ROTAVAC 5D, or two doses of ROTARIX®. Study vaccines were administered concomitantly with routine immunizations. Blood samples were collected pre-vaccination and 28 days after the last dose. Serum anti-rotavirus IgA antibodies were measured by ELISA, with WC3 and 89-12 rotavirus strains as viral lysates in the assays. The primary analysis was to assess non-inferiority of ROTAVAC 5D to ROTAVAC in terms of the geometric mean concentration (GMC) of serum IgA (WC3) antibodies. Seroresponse and seropositivity were also determined. Safety was evaluated as occurrence of immediate, solicited, unsolicited, and serious adverse events after each dose. RESULTS The study evaluated 388 infants in the per-protocol population. All three vaccines were well tolerated and immunogenic. The post-vaccination GMCs were 14.0 U/mL (95% CI: 10.4, 18.8) and 18.1 U/mL (95% CI: 13.7, 24.0) for the ROTAVAC and ROTAVAC 5D groups, respectively, yielding a ratio of 1.3 (95% CI: 0.9, 1.9), thus meeting the pre-set non-inferiority criteria. Solicited and unsolicited adverse events were similar across all study arms. No death or intussusception case was reported during study period. CONCLUSIONS Among Zambian infants, both ROTAVAC and ROTAVAC 5D were well tolerated and the immunogenicity of ROTAVAC 5D was non-inferior to that of ROTAVAC. These results are consistent with those observed in licensure trials in India and support use of these vaccines across wider geographical areas.
Collapse
Affiliation(s)
- R Chilengi
- Centre for Infectious Disease Research in Zambia, Zambia
| | | | - M Chirwa
- Centre for Infectious Disease Research in Zambia, Zambia
| | - N Sukwa
- Centre for Infectious Disease Research in Zambia, Zambia
| | - C Chipeta
- Centre for Infectious Disease Research in Zambia, Zambia
| | - R M Velu
- Centre for Infectious Disease Research in Zambia, Zambia
| | - N Katanekwa
- Centre for Infectious Disease Research in Zambia, Zambia
| | - S Babji
- The Wellcome Trust Research Laboratory, Vellore, India
| | - G Kang
- The Wellcome Trust Research Laboratory, Vellore, India
| | - M M McNeal
- Department of Pediatrics, University of Cincinnati College of Medicine, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | - N Meyer
- Department of Pediatrics, University of Cincinnati College of Medicine, Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA
| | | | | | | | | | | | | |
Collapse
|
31
|
Wilkinson TMA, Van den Steen P, Cheuvart B, Baudson N, Dodet M, Turriani E, Harrington L, Meyer N, Rondini S, Taddei L, Mukherjee P. Seroprevalence of Bordetella pertussis Infection in Patients With Chronic Obstructive Pulmonary Disease in England: Analysis of the AERIS Cohort. COPD 2021; 18:341-348. [PMID: 33955798 DOI: 10.1080/15412555.2021.1920904] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Pertussis is underdiagnosed and underreported in adults and patients with underlying conditions. Patients with chronic obstructive pulmonary disease (COPD) may be at increased risk of severe pertussis. Understanding the true prevalence of pertussis infections in such patients is important. We therefore evaluated the seroprevalence of anti-pertussis toxin (PT) antibodies in a cohort of 40-85-year-old patients diagnosed with moderate, severe or very severe COPD enrolled (between June 2011 and June 2012) in the prospective, observational "Acute Exacerbation and Respiratory InfectionS in COPD" (AERIS; NCT01360398) study, conducted in England. Serum anti-PT antibodies were measured in 104 patients using an enzyme-linked immunosorbent assay on samples collected 12 months (M12) and 24 months (M24) after enrollment. Overall, 14/104 (13.5%) patients had anti-PT concentrations ≥50 IU/mL at M12 or M24, indicative of exposure to Bordetella pertussis during the preceding 2-3 years. Of these, 6/104 (5.8%) had anti-PT ≥70 IU/mL, of whom 3/104 (2.9%) had anti-PT ≥120 IU/mL, indicative of exposure within 12 and 6 months, respectively. These results show a high circulation of B. pertussis in 40-85-year-old patients with moderate, severe or very severe COPD in England between 2012 and 2014, and call for enhanced immunization to prevent pertussis infections in such patients.
Collapse
Affiliation(s)
- Tom M A Wilkinson
- Faculty of Medicine, Clinical and Experimental Sciences, University of Southampton, Southampton General Hospital, Southampton, UK.,Southampton NIHR Respiratory Biomedical Research Unit, Southampton General Hospital, Southampton, UK.,Wessex Investigational Sciences Hub, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, UK
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Asatryan A, Meyer N, Scherbakov M, Romanenko V, Osipova I, Galustyan A, Shamsheva O, Latysheva T, Myasnikova T, Baudson N, Dodet M, Xavier S, Harrington L, Kuznetsova A, Campora L, Van den Steen P. Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study. Hum Vaccin Immunother 2021; 17:723-730. [PMID: 32845735 PMCID: PMC7993191 DOI: 10.1080/21645515.2020.1796423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
As vaccine-induced immunity and protection following natural pertussis infection wane over time, adults and adolescents may develop pertussis and become transmitters to unprotected infants. In Russia, diphtheria and tetanus but not pertussis-containing vaccines are registered for older children, adolescents, or adults. The reduced-antigen-content diphtheria toxoid, tetanus toxoid, and acellular pertussis (dTpa) vaccine (Boostrix, GSK) was developed for booster vaccination of children ≥4 years of age, adolescents, and adults. A phase III, open-label, non-randomized study was performed in eight centers in Russia between January and July 2018. The objective of this study was to assess immunogenicity, reactogenicity and safety of a single dose of dTpa vaccine in healthy Russian participants ≥4 years of age (age categories 4-9 years, 10-17 years, 18-64 years, and ≥65 years). At 1 month post-booster vaccination, across all age groups, >99.0% of participants were seroprotected against diphtheria and tetanus and >96.0% of participants were seropositive for anti-pertussis antibodies. For all antibodies across all age groups, antibody GMCs increased from pre- to 1 month post-booster vaccination and booster responses to diphtheria (in 71.5% of participants), tetanus (85.3%), and pertussis antigens (≥85.6%) were observed. One serious adverse event that was not causally related to the study vaccine was reported. No fatal cases were reported throughout the study period. In conclusion, administration of the dTpa vaccine as a booster dose in healthy Russian participants induced a robust immune response to all vaccine antigens and was generally well tolerated across all age groups.
Collapse
Affiliation(s)
| | | | | | | | | | - Anna Galustyan
- Medical Technologies Ltd, St. Petersburg, Russian Federation.,Federal State Budgetary Educational Institution of Higher Education, St. Petersburg State Pediatric Medical University of the Ministry of Healthcare of the Russian Federation, St. Petersburg, Russian Federation
| | - Olga Shamsheva
- Pirogov Russian National Research Medical University, Moscow, Russian Federation
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Funck-Brentano E, Malissen N, Roger A, Lebbé C, Deilhes F, Frénard C, Dréno B, Meyer N, Grob JJ, Tétu P, Saiag P. Which adjuvant treatment for patients with BRAF V600-mutant cutaneous melanoma? Ann Dermatol Venereol 2021; 148:145-155. [PMID: 33579557 DOI: 10.1016/j.annder.2020.11.006] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2020] [Revised: 10/22/2020] [Accepted: 11/05/2020] [Indexed: 12/21/2022]
Abstract
Treatment of patients with melanoma has considerably improved over the past decade and more recently with adjuvant therapies for patients with American Joint Committee on Cancer (AJCC) stage III (loco-regional metastases) or IV (distant metastases) totally resected melanoma, in order to prevent recurrence. In the adjuvant setting, two options are available to patients with BRAFV600-mutant AJCC stage III totally resected melanoma: anti-PD-1 blockers (nivolumab or pembrolizumab) or BRAF plus MEK inhibitors (dabrafenib plus trametinib). In the absence of comparative studies, it is difficult to determine which of these options is best. Our aim was to review published studies focusing on the management of patients with BRAFV600-mutant melanoma in the adjuvant setting. We also reviewed the main clinical trials of BRAF plus MEK inhibitors and immunotherapy in advanced (i.e. unresectable metastatic) BRAF-mutant melanoma in an attempt to identify results potentially affecting the management of patients on adjuvants. More adverse events are observed with targeted therapy, but all resolve rapidly upon drug discontinuation, whereas with immune checkpoint blockers some adverse events may persist. New therapeutic strategies are emerging, notably neoadjuvant therapies for stage III patients and adjuvant therapies for stage II patients; the place of the adjuvant strategy amidst all these options will soon be re-evaluated. The choice of adjuvant treatment could influence the choice of subsequent treatments in neo-adjuvant or metastatic settings. This review will lead clinicians to a better understanding of the different adjuvant treatments available for patients with totally resected AJCC stage III and IV BRAFV600-mutant melanoma before considering subsequent treatment strategies.
Collapse
Affiliation(s)
- E Funck-Brentano
- Department of General and Oncologic Dermatology, Ambroise-Paré hospital, AP-HP, Boulogne-Billancourt, France; Research unit EA4340 "Biomarkers and clinical trials in oncology and onco-hematology", Versailles-Saint-Quentin-en-Yvelines University, Paris-Saclay University, France.
| | - N Malissen
- Department of Dermatology and Skin Cancer, Aix-Marseille University, AP-HM, Hôpital Timone, Marseille, France
| | - A Roger
- Department of General and Oncologic Dermatology, Ambroise-Paré hospital, AP-HP, Boulogne-Billancourt, France; Research unit EA4340 "Biomarkers and clinical trials in oncology and onco-hematology", Versailles-Saint-Quentin-en-Yvelines University, Paris-Saclay University, France
| | - C Lebbé
- Inserm U976, Department of Dermatology, Dermatology, Paris University, Hôpital Saint-Louis, AP-HP, Paris, France
| | - F Deilhes
- Dermatology Department, CHU de Toulouse, Toulouse, France
| | - C Frénard
- Department of Dermatology, CRCINA, CIC1413, CHU de Nantes, université de Nantes, Nantes, France
| | - B Dréno
- Department of Dermatology, CRCINA, CIC1413, CHU de Nantes, université de Nantes, Nantes, France
| | - N Meyer
- Dermatology Department, CHU de Toulouse, Toulouse, France
| | - J-J Grob
- Department of Dermatology and Skin Cancer, Aix-Marseille University, AP-HM, Hôpital Timone, Marseille, France
| | - P Tétu
- Department of Dermatology, CRCINA, CIC1413, CHU de Nantes, université de Nantes, Nantes, France
| | - P Saiag
- Department of General and Oncologic Dermatology, Ambroise-Paré hospital, AP-HP, Boulogne-Billancourt, France; Research unit EA4340 "Biomarkers and clinical trials in oncology and onco-hematology", Versailles-Saint-Quentin-en-Yvelines University, Paris-Saclay University, France
| |
Collapse
|
34
|
Sauvage M, Tavitian S, Sibaud V, Boulinguez S, Pages-Laurent C, Lamant L, Tournier E, Recher C, Meyer N. Aggressive locoregional behavior of cutaneous squamous cell carcinoma during ruxolitinib use. Ann Dermatol Venereol 2021; 148:140-141. [PMID: 33478822 DOI: 10.1016/j.annder.2020.10.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2020] [Revised: 08/26/2020] [Accepted: 10/23/2020] [Indexed: 01/08/2023]
Affiliation(s)
- M Sauvage
- Department of Dermatology, Institut Universitaire du Cancer de Toulouse, Centre Hospitalier Universitaire de Toulouse, Université Paul-Sabatier Toulouse-III, 31100 Toulouse, France
| | - S Tavitian
- Department of Hematology, Institut Universitaire du Cancer de Toulouse - Oncopole, Centre Hospitalier Universitaire de Toulouse, 31100 Toulouse, France
| | - V Sibaud
- Department of Oncodermatology, Institut Universitaire du Cancer de Toulouse - Oncopole, 31100 Toulouse, France
| | - S Boulinguez
- Department of Dermatology, Institut Universitaire du Cancer de Toulouse, Centre Hospitalier Universitaire de Toulouse, Université Paul-Sabatier Toulouse-III, 31100 Toulouse, France
| | - C Pages-Laurent
- Department of Oncodermatology, Institut Universitaire du Cancer de Toulouse - Oncopole, 31100 Toulouse, France
| | - L Lamant
- Department of Histopathology, Institut Universitaire du Cancer de Toulouse - Oncopole, Centre Hospitalier Universitaire de Toulouse, 31100 Toulouse, France
| | - E Tournier
- Department of Histopathology, Institut Universitaire du Cancer de Toulouse - Oncopole, Centre Hospitalier Universitaire de Toulouse, 31100 Toulouse, France
| | - C Recher
- Department of Hematology, Institut Universitaire du Cancer de Toulouse - Oncopole, Centre Hospitalier Universitaire de Toulouse, 31100 Toulouse, France
| | - N Meyer
- Department of Dermatology, Institut Universitaire du Cancer de Toulouse, Centre Hospitalier Universitaire de Toulouse, Université Paul-Sabatier Toulouse-III, 31100 Toulouse, France.
| |
Collapse
|
35
|
Fredeau L, Hober C, Pham-Ledard A, Boubaya M, Herms F, Celerier P, Aubin F, Beneton N, Dinulescu M, Jannic A, Meyer N, Duval Modeste AB, Cesaire L, Neidhardt EM, Archier E, Dreno B, Lesage C, Berthin C, Kramkimel N, Grange F, De Quatrebarbes J, Stoebner P, Poulalhon N, Arnault J, Abed S, Bonniaud B, Darras S, Heidelberger V, Devaux S, Moncourier M, Misery L, Mansard S, Etienne M, Brunet-Possenti F, Jacobzone C, Lesbazeilles R, Skowron F, Sanchez J, Catala S, Samimi M, Tazi Y, Spaeth D, Gaudy-Marqueste C, Collard O, Triller R, Pracht M, Dumas M, Peuvrel L, Combe P, Lauche O, Guillet P, Reguerre Y, Kupfer-Bessaguet I, Solub D, Schoeffler A, Bedane C, Dalac S, Mortier L, Maubec E. Cémiplimab et carcinomes épidermoïdes cutanés localement évolués ou métastatiques : premières données de vie réelle. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
36
|
Brun A, Lamant L, Meyer N, Tournier E, Fradet M, Boulinguez S, Ysebaert L, Sibaud V. Dermatose éosinophilique associée aux hémopathies (EDHM) : une dermatose vraiment pas saisonnière ? Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
37
|
Maubec E, Boubaya M, Petrow P, Beylot-Barry M, Basset-Seguin N, Deschamps L, Grob J, Dréno B, Scheer-Senyarich I, Bloch-Queyrat C, Leccia MT, Stefan A, Saiag P, Grange F, Meyer N, de Quatrebarbes J, Dinulescu M, Legoupil D, Machet L, Dereure O, Zehou O, Montaudié H, Wierzbicka-Hainaut E, Le Corre Y, Mansard S, Guegan S, Arnault JP, Dalac S, Aubin F, Alloux C, Lopez I, Cherbal S, Tibi A, Dalac S, Levy V. Étude de phase II de l’administration de pembrolizumab (MK-3475) en monothérapie et en première ligne chez des patients présentant un carcinome épidermoïde cutané non opérable. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
38
|
Pages C, Deilhes F, Tauber M, Boulinguez S, Meyer N, Sibaud V. Gestion des toxicités cutanées sévères induites par l’immunothérapie : la place du dupilumab. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
39
|
Khammari A, Dinulescu M, Nguyen JM, Cassecuel J, Maillard H, Le Duff F, Machet L, Beylot-Barry M, Legoupil D, Wierzbicka-Hainaut E, Bedane C, Leccia MT, Debarbieux S, Meyer N, Monestier S, Bens G, Denis M, Vourch M, Bossard C, Vergier B, Dréno B. L’efficacité de l’imiquimod dans la prise en charge du mélanome de Dubreuilh in situ (lentigo malin). Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
40
|
Martinón-Torres F, Halperin SA, Nolan T, Tapiero B, Perrett KP, de la Cueva IS, García-Sicilia J, Stranak Z, Vanderkooi OG, Kosina P, Virta M, Merino Arribas JM, Miranda-Valdivieso M, Arias Novas B, Bozensky J, Cilleruelo Ortega M, Ramos Amador JT, Baca M, Escribano PE, Zuccotti GV, Janota J, Marchisio PG, Kostanyan L, Meyer N, Ceregido MA, Cheuvart B, Kuriyakose SO, Mesaros N. Immunantwort auf die DTPa-HBV-IPV/Hib-Auffrischimpfung bei Kleinkindern von Müttern, die während der Schwangerschaft mit Tdap-Impfstoff geimpft worden waren: Folgestudie einer randomisierten, placebokontrollierten Studie. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- F Martinón-Torres
- Hospital Clínico Universitario de Santiago, Pediatría Clínica, Infectológica y Traslacional
| | - SA Halperin
- Dalhousie University, Canadian Center for Vaccinology
| | - T Nolan
- University of Melbourne, Murdoch Children’s Research Institute and Melbourne School of Population and Global Health
| | - B Tapiero
- Université de Montréal, CHU Sainte Justine
| | - KP Perrett
- University of Melbourne, Murdoch Children’s Research Institute and Melbourne School of Population and Global Health
| | - IS de la Cueva
- Instituto Hispalense de Pediatría, Unidad de Investigación
| | - J García-Sicilia
- Hospital Universitario Madrid Sanchinarro, Servicio de Pediatría
| | - Z Stranak
- Institute for the Care of Mother and Child, Neonatology Department
| | - OG Vanderkooi
- Alberta Children’s Hospital, University of Calgary, Departments of Pediatrics, Microbiology, Immunology and Infectious DiseasesPathology and Laboratory Medicine and Community Health Sciences, Pathology and Laboratory Medicine and Community Health Sciences, Alberta Children’s Hospital Research Institut
| | - P Kosina
- University Hospital, Department of Infectious Diseases
| | - M Virta
- Tampere University, Tampere Vaccine Research Center
| | | | | | - B Arias Novas
- Hospital Universitario Sanitas La Zarzuela, Servicio de Pediatría
| | - J Bozensky
- Vitkovice Hospital, Pediatrics Department
| | | | | | - M Baca
- Hospital Quiron Malaga, Departamento de Pediatría y Neonatología
| | | | - GV Zuccotti
- University of Milan, Ospedale dei Bambini Vittore Buzzi
| | - J Janota
- Thomayer Hospital Prague, Department of Neonatology
| | - PG Marchisio
- University of Milan, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
| | | | | | | | | | | | | |
Collapse
|
41
|
Romanenko V, Osipova I, Galustyan A, Scherbakov M, Baudson N, Farhi D, Anaya L, Kuriyakose SO, Meyer N, Janssens W. Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study. Hum Vaccin Immunother 2020; 16:2265-2273. [PMID: 32048889 PMCID: PMC7553713 DOI: 10.1080/21645515.2020.1720437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
We assessed the immunogenicity and safety of the combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus/Haemophilus influenzae type b vaccine (DTPa-IPV/Hib) in children in Russian Federation aiming to support the registration of the vaccine in Russia. In this phase 3, non-randomized, open-label study (NCT02858440), healthy children received three primary doses at 3, 4.5, and 6 months of age (N = 235) and a booster dose at 18 months of age (N = 225). Seroprotection rates against diphtheria, tetanus, Hib, and poliovirus 1–3, seropositivity rates against pertussis antigens, and antibody geometric mean concentrations/titers for all antigens were evaluated one month post-primary and post-booster vaccinations. Solicited local and general adverse events (AEs) were collected during a 4-day period and unsolicited AEs during a 31-day period post-vaccination. Serious AEs were recorded throughout the study. At post-primary vaccination, all infants were seroprotected against diphtheria, tetanus, and poliovirus 1 and 2, 99.3% against poliovirus 3, and 98.4% against Hib. At least 98.9% of participants were seropositive for the three pertussis antigens. At post-booster vaccination, all toddlers were seroprotected/seropositive against all vaccine components. The most frequent local and general solicited AEs were redness, reported for 52.6% and 44.9% of children, and irritability, reported for 64.7% and 39.1% of children, post-primary and post-booster vaccination, respectively. Unsolicited AEs were reported for 20.4% (post-primary) and 5.8% of children (post-booster vaccination). Most AEs were mild or moderate in intensity. Six serious AEs were reported in three (0.4%) children; none were fatal or assessed as vaccination-related. DTPa-IPV/Hib proved immunogenic and well tolerated in the Russian pediatric population.
Collapse
Affiliation(s)
| | | | - Anna Galustyan
- Medical Technologies Ltd , St. Petersburg, Russian Federation
| | | | | | | | | | | | | | | |
Collapse
|
42
|
Saiag P, Meyer N, Dutriaux C, Verdoni L, Morsli O, Spampinato A, Lattenist L, Mortier L, Grob JJ. 1121P Factors predicting overall survival (OS) and progression-free survival (PFS) in real-life: Classification and regression tree analysis of a 5-year (5Y) cohort follow-up study of advanced melanoma patients (pts) that have initiated pembrolizumab. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
43
|
Konstantinou MP, Lucas P, Uthurriague C, Severino-Freire M, Spenatto N, Gaudin C, Lamant L, Tournier E, Bulai-Livideanu C, Meyer N, Paul C. Langerhans cell histiocytosis associated with chronic myelomonocytic leukaemia both harbouring the same BRAF V600E mutation: efficacy of vemurafenib. J Eur Acad Dermatol Venereol 2020; 35:e120-e121. [PMID: 32757402 DOI: 10.1111/jdv.16850] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 07/22/2020] [Accepted: 07/30/2020] [Indexed: 01/09/2023]
Affiliation(s)
- M P Konstantinou
- Dermatology Department, Paul Sabatier University, University Hospital of Toulouse, Toulouse, France
| | - P Lucas
- Dermatology Department, Paul Sabatier University, University Hospital of Toulouse, Toulouse, France
| | - C Uthurriague
- Dermatology Department, Paul Sabatier University, University Hospital of Toulouse, Toulouse, France
| | - M Severino-Freire
- Dermatology Department, Paul Sabatier University, University Hospital of Toulouse, Toulouse, France
| | - N Spenatto
- Center of Sexually Transmitted Diseases, Dermatology department and social medicine, University Hospital of Toulouse, Toulouse, France
| | - C Gaudin
- Geriatrics Department, University Hospital of Toulouse, Toulouse, France
| | - L Lamant
- Pathology Department, University Institute of Cancer Toulouse Oncopole and University Hospital of Toulouse, Toulouse, France
| | - E Tournier
- Pathology Department, University Institute of Cancer Toulouse Oncopole and University Hospital of Toulouse, Toulouse, France
| | - C Bulai-Livideanu
- Dermatology Department, Paul Sabatier University, University Hospital of Toulouse, Toulouse, France
| | - N Meyer
- Dermatology Department, IUC and CHU de Toulouse, Toulouse, France
| | - C Paul
- Dermatology Department, Paul Sabatier University, University Hospital of Toulouse, Toulouse, France
| |
Collapse
|
44
|
Mohr P, Tadmouri A, Suissa J, Alivon M, Meyer N. 1140P A digital companion for patients with BRAF-mutant advanced melanoma treated with targeted therapies: TAVIE skin app. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1263] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
45
|
Hober C, Fredeau L, Ledard AP, Boubaya M, Herms F, Aubin F, Benetton N, Dinulescu M, Jannic A, Cesaire L, Meyer N, Modeste AD, Archier E, Lesage C, Kramkimel N, Arnault J, Grange F, Dalac S, Mortier L, Maubec E. 1086P Cemiplimab for advanced cutaneous squamous cell carcinoma: Real life experience. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1210] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
46
|
Fabacher T, Schaeffer M, Tuzin N, Séverac F, Lefebvre F, Mielcarek M, Sauleau EA, Meyer N, Godet J. [Medical biostatistics with GMRC Shiny Stats - learning by doing]. Ann Pharm Fr 2020; 78:499-506. [PMID: 32565157 DOI: 10.1016/j.pharma.2020.06.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2020] [Revised: 05/29/2020] [Accepted: 06/05/2020] [Indexed: 10/24/2022]
Abstract
Biostatistics are omnipresent in the scientific and medical literature and are an essential skill for any health student. We have developed a practical training tool - GMRC Shiny stats - an interactive application specifically dedicated to medical data statistical analysis. The application has been designed to provide an analysis workflow corresponding to the usual progression of an experienced statistician during data analysis. The most common statistical analyses can be performed (descriptive statistics, inferences according to frequentist methods, survival analyses, correlation, agreement measurements, etc.). GMRC Shiny stats is intuitive and user-friendly and assists students in choosing the most appropriate statistical tests. With all these functionalities, students can learn statistical analysis by doing. Getting involved in the statistical analysis and processing of their own data is likely to improve their biostatistics skills.
Collapse
Affiliation(s)
- T Fabacher
- Groupe méthode en recherche clinique-hôpitaux universitaires de Strasbourg, 1, place de l'hôpital, 67000 Strasbourg, France
| | - M Schaeffer
- Société Alstats, 3, route de Kientzville, 67750 Scherwiller, France
| | - N Tuzin
- Groupe méthode en recherche clinique-hôpitaux universitaires de Strasbourg, 1, place de l'hôpital, 67000 Strasbourg, France
| | - F Séverac
- Groupe méthode en recherche clinique-hôpitaux universitaires de Strasbourg, 1, place de l'hôpital, 67000 Strasbourg, France
| | - François Lefebvre
- Groupe méthode en recherche clinique-hôpitaux universitaires de Strasbourg, 1, place de l'hôpital, 67000 Strasbourg, France
| | - M Mielcarek
- Groupe méthode en recherche clinique-hôpitaux universitaires de Strasbourg, 1, place de l'hôpital, 67000 Strasbourg, France
| | - E-A Sauleau
- Groupe méthode en recherche clinique-hôpitaux universitaires de Strasbourg, 1, place de l'hôpital, 67000 Strasbourg, France
| | - N Meyer
- Groupe méthode en recherche clinique-hôpitaux universitaires de Strasbourg, 1, place de l'hôpital, 67000 Strasbourg, France
| | - J Godet
- Groupe méthode en recherche clinique-hôpitaux universitaires de Strasbourg, 1, place de l'hôpital, 67000 Strasbourg, France.
| |
Collapse
|
47
|
Masson Regnault M, Fraitag S, Lamant L, Maza A, De la Fouchardière A, Tournier E, Lauwers F, Carfagna L, Meyer N, De Berail A, Busam KJ, Lazova R, Mazereeuw-Hautier J. [The role of new molecular tests in the diagnosis of melanoma in a setting of congenital nævus in an infant]. Ann Dermatol Venereol 2020; 147:746-754. [PMID: 32451177 DOI: 10.1016/j.annder.2020.03.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2019] [Revised: 01/14/2020] [Accepted: 03/10/2020] [Indexed: 10/24/2022]
Abstract
INTRODUCTION Congenital and infantile melanomas are extremely rare. We report a case of a child presenting at birth with a giant congenital nevus complicated by melanoma and on long-term follow-up with exploration using new immunohistochemistry and molecular biology tools. OBSERVATION A new-born girl presented at birth with a large congenital cervico-mandibular tumour with para-pharyngeal extension and underlying osteolysis. At 7 months, histology and immunohistochemistry of the operative specimen revealed nodules with atypical features (mitotic figures, necrosis and positive expression of KI67 and P53 in approximatively 50 % of the melanocytic nuclei). A diagnosis was made of infantile melanoma associated with congenital nevi. Repeated surgery and monitoring (clinical and imaging) were performed. At the age of 7 years, as there was no evidence of metastatic lesions, further analyses were performed on the initial operative specimen. Investigation of transcription factor expression using immunohistochemistry, comparative genomic hybridization and histology-guided mass spectrometry, although suspect, did not in itself support a diagnosis of melanoma. Finally, at the age of 7 years, hepatic and pulmonary metastases were reported. Despite combined immunotherapy with ipilimumab and nivolumab, the child died 5 months later. CONCLUSION This case illustrates the complexity of diagnosis of infantile melanoma and the risk of metastatic involvement long after the initial diagnosis. Diagnosis may be difficult and necessitates expert advice and the application of several recent methods to reach a conclusion and initiate appropriate treatment.
Collapse
Affiliation(s)
- M Masson Regnault
- Service de dermatologie, centre de références de maladies rares de la peau et des muqueuses, université Paul-Sabatier, hôpital Larrey, CHU de Toulouse, 24, chemin du Pouvourville, 31400 Toulouse, France; Pathology department, Samaritan Drive, San Jose, États-Unis.
| | - S Fraitag
- Service d'anatomopathologie, groupe hospitalier Necker-Enfants-Malades, AP-HP, Paris, France
| | - L Lamant
- Service d'anatomopathologie, CHU de Toulouse, Toulouse, France
| | - A Maza
- Service de dermatologie, centre de références de maladies rares de la peau et des muqueuses, université Paul-Sabatier, hôpital Larrey, CHU de Toulouse, 24, chemin du Pouvourville, 31400 Toulouse, France
| | | | - E Tournier
- Service d'anatomopathologie, CHU de Lyon, Lyon, France
| | - F Lauwers
- Service de chirurgie maxillo-faciale, CHU Purpan, Toulouse, France
| | - L Carfagna
- Service d'oncodermatologie, institut universitaire du Cancer, Toulouse-Oncopole, CHU de Toulouse, Toulouse, France
| | - N Meyer
- Service d'oncodermatologie, institut universitaire du Cancer, Toulouse-Oncopole, CHU de Toulouse, Toulouse, France
| | - A De Berail
- Service de chirurgie maxillo-faciale, CHU Purpan, Toulouse, France
| | - K J Busam
- Pathology department, Memorial Sloan-Kettering Cancer Center, New York, États-Unis
| | - R Lazova
- Pathology department, Samaritan Drive, San Jose, États-Unis; Service de dermatologie, hôpital Jean-Bernard, CHU de Poitiers, Poitiers, France
| | - J Mazereeuw-Hautier
- Service de dermatologie, centre de références de maladies rares de la peau et des muqueuses, université Paul-Sabatier, hôpital Larrey, CHU de Toulouse, 24, chemin du Pouvourville, 31400 Toulouse, France
| |
Collapse
|
48
|
Becker S, Meyer N, Xu H, Wax JF. Viscosity of liquid Na-K alloys from molecular dynamics simulations. J Phys Condens Matter 2020; 32:194005. [PMID: 31952054 DOI: 10.1088/1361-648x/ab6d13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
The shear viscosity of liquid Na-K alloys is computed from molecular dynamics simulations using the Green-Kubo formalism. Interatomic interactions are described using effective pair potentials obtained from Fiolhais pseudo-potential and self-consistent screening. The composition dependence of the viscosity is first investigated at 373 K, then its temperature dependence at three different compositions, namely Na10-K90, Na50-K50, and Na90-K10. Simulation results are first compared with available experimental data. The evolution of the viscosity of the alloys versus temperature is similar to that of a pure one component fluid. This is discussed in connection with the chemical order of the mixtures.
Collapse
Affiliation(s)
- S Becker
- Université de Lorraine LCP-A2MC 1, boulevard Arago 57070 METZ Cédex, France
| | | | | | | |
Collapse
|
49
|
Calabre C, Schuller E, Goltzene MA, Rongières C, Celebi C, Meyer N, Teletin M, Pirrello O. Follicular flushing versus direct aspiration in poor responder IVF patients: a randomized prospective study. Eur J Obstet Gynecol Reprod Biol 2020; 248:118-122. [DOI: 10.1016/j.ejogrb.2020.03.003] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2019] [Revised: 02/28/2020] [Accepted: 03/05/2020] [Indexed: 12/25/2022]
|
50
|
Hughes B, Gonzalez RM, Basset-Seguin N, Vornicova O, Schachter J, Joshi A, Meyer N, Grange F, Piulats J, Bauman J, Chirovsky D, Zhang P, Gumuscu B, Swaby R, Grob J. Health-Related Quality of Life of Pembrolizumab for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma in KEYNOTE-629. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2019.11.360] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|